Cell-matrix impedance monitoring of cancer cells of different lineages, origins or stages
By monitoring the interaction between cancer cells and effector cells in a multi-chamber box, and evaluating the cancer treatment effect using cell-matrix impedance parameters, the problem of difficult to predict treatment response in the prior art is solved, and efficient screening of different cancer cells is achieved and Selection of personalized treatment options.
Patent Information
- Application Number
- CN202410879080.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-08-01
- Filing Date
- 2018-08-01
- Publication Date
- 2024-11-05
AI Technical Summary
Existing cancer treatment methods are difficult to effectively predict responses to different cancer cells, resulting in patients requiring multiple treatment options and lacking therapies with high-efficiency screening potential.
Provide a method based on cell-matrix impedance monitoring to monitor cell-matrix impedance by preloading cancer cells of different lineages, origins or stages in a multi-chamber box and interacting with effector cells to evaluate anti-cancer treatments. Effect. The method includes using a box with a plurality of chambers, each equipped with an array of electrodes, adding effector cells and compounds to the chamber, comparing impedance parameters over time, and determining the killing effect.
This method can effectively evaluate the killing effect of anti-cancer treatment on different cancer cells, improve the screening efficiency of treatment plans, provide personalized treatment plans, and reduce the risk of treatment failure.
Smart Images

Figure CN118897074A_ABST
Abstract
Description
This application is a divisional application of the Chinese patent application with application number 201880064110.0 (application date: August 1, 2018, invention name: Cell-matrix impedance monitoring of cancer cells of different lineages, origins or stages). CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 539,955, filed on August 1, 2017, which is incorporated herein by reference in its entirety. Technical Field
[0002] The present invention relates to cell-matrix impedance monitoring of cancer cells, and more specifically, to a method for evaluating the effect of anti-cancer therapy on cancer cells pre-loaded on a cell-matrix impedance-based cartridge, and also to a cell-matrix impedance monitoring cartridge that can be coupled to a cell culture device (e.g., a bioreactor for aseptically transferring effector cells to the cell-matrix impedance monitoring cartridge). Background Art
[0003] Cancer is a group of diseases that involve abnormal cell growth that may invade or spread to other parts of the body. When cancer starts, it does not produce any symptoms. Symptoms appear as a lump grows or an ulcer forms. Cancer can spread from its original site by spreading locally, through the lymph nodes to local lymph nodes, or through the blood to distant sites, which is called metastasis. When it spreads through the blood, it usually spreads throughout the body. Cancer causes about 14% of human deaths.
[0004] There are many ongoing technologies for treating cancer. These include the development of new chemotherapeutic agents. Chemotherapy generally refers to the use of agents or drugs to treat cancer. A more recent experimental approach is adoptive cell transfer (ACT), which involves transferring cells into a patient. In different variations, the cells can come from the same patient or from another individual.
[0005] To date, patients are not universally responsive to any particular cancer treatment, and predicting which treatment will be effective can be difficult. Therefore, during the course of cancer, patients often try different treatments. Therefore, there remains a need to develop methods and systems to improve the screening of potential therapies for cancer cells. Summary of the invention
[0006] The present invention provides a cell-based assay that can effectively test the effects of proposed anti-cancer treatments on cancer cells pre-loaded in a cartridge, and also provides a cell-matrix impedance monitoring cartridge that can be aseptically connected to a cell culture device for aseptic transfer of samples (such as effector cells or engineered effector cells).
[0007] In one aspect of the present invention, a method for evaluating cell lysis of cancer cells is provided, the method comprising: providing a cell-matrix impedance monitoring box having multiple chambers, each chamber having an electrode array configured to measure cell-matrix impedance, wherein different chambers are pre-loaded with different target cells, specifically cancer cells of different lineages, origins or stages; adding effector cells to the multiple chambers to interact with the target cells, wherein the effector cells are immune cells; monitoring the cell-matrix impedance of the multiple chambers before and after adding the effector cells, and optionally deriving impedance-based parameters from the impedance; and determining the killing effect of the effector cells on different target cells by comparing the impedance or impedance-based parameters over time.
[0008] The box can be implemented in various forms. In a preferred embodiment, the box can be implemented as a multi-chamber box (such as a multi-well plate), wherein one or more chambers are accessible by removing a lid, which is convenient for direct loading into the chamber. In other embodiments, the top of at least one chamber is sealed, and the box has a channel system that is configured to transport fluids in and out of the chamber. In addition, the channel system can be configured with ports for transporting fluids into and out of the box. The channel system can be configured to receive effector cells, cell culture media, and / or reagents into the chamber.
[0009] In some embodiments, the automated robotic system transfers cells directly into the chamber of the box, but in other embodiments, the box is fluidly coupled to a culture device in which cells are cultured, maintained or stored for transmission through the channel system. In further embodiments, the cell culture device is a cell culture dish or bottle. In other embodiments, the cell culture device is a bioreactor. In further embodiments, the bioreactor is a wave swing bioreactor. In further embodiments, the cell culture device is a cell bag bioreactor system. The cell-matrix impedance monitoring box can be sterilely coupled or connected to various bioreactors through transmission lines, valves and / or pumps to maintain sterility.
[0010] In some embodiments, the box uses an electrode array with multiple measuring electrodes and a single reference electrode in at least one chamber to monitor cell-matrix impedance. In other embodiments, the box uses an electrode array with only a single measuring electrode and a single reference electrode in at least one chamber to monitor cell-matrix impedance. In other embodiments, the box can use an interdigitated electrode array in at least one chamber to monitor cell-matrix impedance.
[0011] In some embodiments, the box has a plurality of different chambers for accommodating different target cells from the same tissue origin. In other embodiments, the box has a plurality of different chambers for accommodating different target cells from different tissue origins. Preferably, different target cells are preloaded by a certain facility, which maintains cancer cells from different tissue origins and distributes the preloaded box to consumers. Non-limiting examples of such tissue origins include breast tissue, lung tissue, colon tissue, mesenchymal cells or fibroblasts (e.g., fibrosarcoma), prostate tissue, kidney tissue, epidermal tissue, liver tissue, and ovarian tissue. Different target cells in the same tissue origin can be different cell lines, different primary cells, or can be different due to mutations, genotypes, or cancer stages (e.g., 0, I, IIa, IIb, III, IV phases, etc.). Different target cells (e.g., lung cancer cells) with the same tissue origin can be different due to different gene expressions and / or different protein expressions. Different gene expressions can include genes with different mutations, different overexpressed genes, etc. Different protein expressions can include expressing different protein biomarkers or different target proteins by cells.
[0012] The box can also be delivered with at least one empty chamber, thereby allowing the operator to load additional target cells for additional testing. In some cases, the additional target cells are cancer cells obtained from a variety of biological samples such as solid tumors, hematopoietic tumors, blood, and pleural effusions. In some embodiments, the additional target cells are circulating tumor cells (CTCs) collected from blood. In other embodiments, the additional target cells are tumor cells collected from tissue biopsies.
[0013] Effector cells can be any suitable cells of the innate immune system. Non-limiting examples of effector cells that can be used in the method include natural killer cells (NK cells), macrophages, neutrophils, eosinophils, T cells and B cells. When effector cells are T cells, they can be helper T cells (Th cells), cytotoxic T cells and / or memory T cells. In some embodiments, effector cells are tumor infiltrating lymphocytes (TIL), and in further embodiments, TIL can be separated from the cancer tissue of the same patient of the aforementioned collection of other target cancer cells.
[0014] In some embodiments, the effector cells are engineered to display one or more chimeric antigen receptors (CARs) for one or more antigens suspected to be present on at least one target cell type (such as at least one cancer cell lineage, origin or staging). To this end, the method evaluates the effect of engineered effector cells for one or more cancer cell lineages, origins or staging. In some embodiments, the effector cells are CAR-T cells. In some embodiments, each CAR displays one or more single-chain fragment variable (scFv) regions for cancer cell antigens. In a further embodiment, the effector cells display multiple scFVs for two or more different cancer cell antigens present in the same or different cancer cell lineages, origins or staging.
[0015] In accordance with the foregoing, in some embodiments, the effector cells are engineered to increase expression of an exogenous compound (optionally interleukin 2) to promote growth, proliferation, or persistence of the effector cells.
[0016] The method can compare the impedance or impedance-based parameters from a single test chamber to determine the effect; however, in other embodiments, the impedance or impedance-based parameters of the test chamber are compared with the impedance or impedance-based parameters of the control chamber or predetermined control parameters. According to the foregoing, in one embodiment, the method may include adding non-engineered effector cells from the same subject (e.g., non-engineered effector cells do not display chimeric antigen receptor CAR)) to form a control chamber; monitoring the impedance of the control chamber, and optionally deriving impedance-based parameters according to the impedance of the control chamber; and comparing the impedance or impedance-based parameters between the control chamber and the chamber with engineered effector cells (also referred to as "test chamber") over time to determine the difference in the killing effect of effector cells in the test chamber for a specific cancer cell lineage, origin or stage. The control chamber can be loaded with other types of control cells, which are used as a control for monitoring and determining the cytolysis of target cancer cells by engineered effector cells in the test chamber.
[0017] In some embodiments, the method comprises comparing cell-matrix impedance measurements, but in preferred embodiments, the method comprises comparing impedance-based parameters derived from impedance. Typically, a decrease in impedance or impedance-based parameters over time indicates an increased cytolytic effect on cancer cells.
[0018] In some embodiments, the impedance-based parameter is a single parameter, such as a cell index, a cell change index, or a normalized cell index normalized to a time point before the addition of effector cells. In some embodiments, the impedance-based parameter is an impedance-based curve, and in further embodiments, the killing effect of effector cells on target cells is determined by comparing the impedance-based curve over time. However, in other embodiments, the killing effect of effector cells on target cells is determined by calculating and comparing the percentage of cell lysis of target cells.
[0019] In some embodiments, one or more compounds are evaluated for their cytolytic effects on cancer cells of one or more lineages or origins. Therefore, in some embodiments, the method comprises the steps of: adding another compound, the other compound suspected of enhancing or weakening the killing effect of effector cells on target cells; and determining the difference in effect in response to the addition of the compound. A variety of compounds can be tested, including antibodies or antibody fragments, modified antibodies or antibody fragments or peptides. In some embodiments, the other compound is a checkpoint inhibitor. Checkpoint inhibitors seek to break through a major defense of cancer against immune system attacks by blocking normal proteins on cancer cells. Examples of checkpoint inhibitors include antibodies or antibody fragments targeting PD1, CTLA-4, CD137, OX40, CD27, CD40L, TIM3 on the surface of target effector cells, or their corresponding cognate ligands on the surface of target cells.
[0020] In other embodiments, the additional compound is a bispecific linker, which is defined as at least two polypeptides linked together, wherein at least one polypeptide binds to an effector cell and at least one additional polypeptide binds to a target cell, thereby linking the effector cell to the target cell. In an additional embodiment, the bispecific linker binds to a T cell surface module, such as CD3.
[0021] The above aspects can be further applied to provide a method for determining the treatment of killing patient cancer cells. Specifically, effector cells that are believed to have a cytolytic effect on one or more cancer cell populations can be administered to patients with cancer of a certain tissue origin, such as breast cancer, lung cancer, colon cancer, fibrosarcoma, prostate cancer, kidney cancer, epidermal cancer, liver cancer or ovarian cancer. Alternatively, or in addition, effector cells that are believed to have a cytolytic effect on one or more cancer cell lineages or origins can be further tested for cytolytic effects on cancer cells collected from patient samples.
[0022] Additionally, a method of killing cancer cells in vivo is provided, the method comprising determining a treatment to kill cancer cells in a patient substantially as described above; expanding the population of effector cells; and administering a therapeutically effective amount of the effector cells to the patient.
[0023] In a related aspect of the present invention, a method for evaluating cytolysis of cancer cells is provided, the method comprising: providing a cell-matrix impedance monitoring box having multiple chambers, each chamber having an electrode array configured to monitor cell-matrix impedance, wherein different chambers are pre-loaded with different target cells, specifically cancer cells of different lineages, origins or stages; adding effector cells to the multiple chambers, wherein the effector cells are immune cells; adding bispecific linkers to at least some of the chambers, wherein the bispecific linkers are molecules suspected of bridging the effector cells to at least some of the target cells; monitoring the cell-matrix impedance of the multiple chambers over time, including before and after the step of adding the bispecific linkers, and optionally deriving impedance-based parameters from the impedance; and determining the killing effect of the effector cells on different target cells in response to the bispecific linkers by comparing the impedance or impedance-based parameters over time.
[0024] The box can be implemented in various forms. In a preferred embodiment, the box has a plurality of chambers, each chamber preloaded with target cells. The box can be implemented as a multi-chamber box (such as a multi-well plate), wherein one or more chambers can be accessed by removing a lid. In other embodiments, the top of at least one chamber is sealed, and the box has a channel system, which is configured to transport fluids to and from the chamber. In addition, the channel system can be configured with a port for transporting fluids (e.g., liquids or gases) to and from the box. The channel system can be configured to receive effector cells, cell culture media and / or reagents into the chamber.
[0025] In some embodiments, the automated robotic system transfers cells directly into the chamber of the box, but in other embodiments, the box is fluidly coupled to a culture device that stores cells for transmission through the channel system. In further embodiments, the cell culture device is a cell culture dish or bottle. In other embodiments, the cell culture device is a bioreactor. In further embodiments, the bioreactor is a wave-rocking bioreactor. In further embodiments, the cell culture device is a cell bag bioreactor system. The cell-matrix impedance monitoring box can be aseptically coupled or connected to various bioreactors through transmission lines, valves and / or pumps to maintain sterility.
[0026] In some embodiments, the box uses an electrode array with multiple measuring electrodes and a single reference electrode in at least one chamber to monitor cell-matrix impedance. In other embodiments, the box uses an electrode array with only a single measuring electrode and a single reference electrode in at least one chamber to monitor cell-matrix impedance. In either case, in further embodiments, the box can use an interdigitated electrode array in at least one chamber to monitor cell-matrix impedance.
[0027] In some embodiments, the box has a plurality of different chambers for accommodating different target cells from the same tissue origin. In other embodiments, the box has a plurality of different chambers for accommodating different target cells from different tissue origins. Preferably, different target cells are preloaded by a certain facility, and the facility maintains cancer cells from different tissue origins and distributes the preloaded box to consumers. Non-limiting examples of such tissue origins include breast tissue, lung tissue, colon tissue, mesenchymal cells or fibroblasts (e.g., fibrosarcoma), prostate tissue, kidney tissue, epidermal tissue, liver tissue, and ovarian tissue. Different target cells in the same tissue origin can be different cell lines, different primary cells, or can be different due to mutation, genotype, or cancer stage (e.g., 0, I, IIa, IIb, III, IV phase, etc.). Different target cells (e.g., lung cancer cells) with the same tissue origin can be different due to different gene expressions and / or different protein expressions. Different gene expressions can include genes with different mutations, different overexpressed genes, etc. Different protein expressions can include expressing different protein biomarkers or different target proteins by cells.
[0028] The box can also be delivered with at least one empty chamber, thereby allowing the operator to load additional target cells for additional testing. In some cases, additional target cells are cancer cells obtained from a variety of biological samples such as solid tumors, hematopoietic tumors, blood, and pleural effusions. In some embodiments, additional target cells are circulating tumor cells (CTCs) collected from blood. In other embodiments, additional target cells are tumor cells collected from tissue biopsies.
[0029] Effector cells can be any suitable cells of the innate immune system. Non-limiting examples of effector cells that can be used in the method include natural killer cells (NK cells), macrophages, neutrophils, eosinophils, T cells and B cells. When effector cells are T cells, they can be helper T cells (Th cells), cytotoxic T cells and / or memory T cells. In some embodiments, effector cells are tumor infiltrating lymphocytes (TILs), and in further embodiments, they can be separated from the cancer tissue of the same patient from which the aforementioned other target cancer cells have been collected.
[0030] Effector cells can be engineered to display one or more chimeric antigen receptors (CARs) for one or more antigens suspected to be present in at least one cancer cell lineage, origin or staging. To this end, the method evaluates the effect of engineered effector cells for one or more cancer cell lineages, origins or staging and bispecific adapters. In some embodiments, the effector cell is a CAR-T cell. In some embodiments, each CAR displays one or more single-chain fragment variable (scFv) regions for cancer cell antigens. In a further embodiment, effector cells display multiple scFVs for two or more different cancer cell antigens present in the same or different cancer cell lineages, origins or staging.
[0031] In accordance with the foregoing, in some embodiments, the effector cells are further engineered to increase expression of an exogenous compound (optionally interleukin 2) to promote growth, proliferation or persistence of the effector cells.
[0032] In some embodiments, the bispecific linker comprises two polypeptides linked together, wherein each polypeptide binds to an effector cell or a target cell, thereby bridging the effector cell and the target cell. In some embodiments, the bispecific linker binds to a T cell surface module, optionally a cluster of differentiation 3 (CD3).
[0033] In some embodiments, the method comprises comparing cell-matrix impedance measurements, but in preferred embodiments, the method comprises comparing impedance-based parameters derived from the impedance. Typically, a decrease in impedance or impedance-based parameters over time indicates an increased cytolytic effect on cancer cells.
[0034] In some embodiments, the impedance-based parameter is a single parameter, such as a cell index, a cell change index, or a normalized cell index normalized to a time point before the addition of the bispecific linker. In some embodiments, the impedance-based parameter is an impedance-based curve, and in further embodiments, the killing effect of the effector cells on the target cells in the presence of the bispecific linker is determined by comparing the impedance-based curve over time. However, in other embodiments, the killing effect of the effector cells on the target cells is determined by calculating and comparing the percentage of cell lysis of the target cells.
[0035] The above aspects can be further applied to provide a method for determining the treatment of killing patient cancer cells. Specifically, a bispecific linker that is considered to have a cytolytic effect against one or more cancer cell lineages, origins or stages can be administered to cancer patients with cancer cells of similar or identical lineages, origins or stages, such as breast cancer, lung cancer, colon cancer, fibrosarcoma, prostate cancer, kidney cancer, epidermal cancer, liver cancer or ovarian cancer. Alternatively, or in addition, the effect of a bispecific linker that is considered to have a cytolytic effect against one or more cancer cell lineages, origins or stages on cancer cells collected from patient samples can be tested.
[0036] In furtherance of the above objectives, there is also provided a method of killing cancer cells in vivo, the method comprising determining a treatment to kill cancer cells in a patient substantially as described above; and administering to the patient a therapeutically effective amount of a bispecific linker.
[0037] In a related aspect, a method for assessing cytolysis of cancer cells is provided, the method comprising: providing a cell-matrix impedance monitoring cartridge and a pump fluidically coupled to a bioreactor, the cartridge having a chamber with an electrode array configured to measure cell-matrix impedance; adding target cells to the chamber and culturing the cells in the bioreactor; pumping cells from the cell culture into the chamber; monitoring the cell-matrix impedance of the chamber before and after adding the cells from the cell culture, and optionally deriving an impedance-based parameter from the impedance; and determining a change in the cell-matrix impedance or an impedance-based parameter in response to pumping the cells into the chamber.
[0038] In another related aspect, a cell-matrix impedance monitoring system is provided, comprising: a cell-matrix impedance monitoring box having a plurality of chambers, each chamber having an electrode array configured to measure cell-matrix impedance; a bioreactor configured to culture cells, the bioreactor fluidly coupled to the box; a pump configured to pump the cultured cells from the bioreactor into the plurality of chambers of the box; and an impedance analyzer electrically coupled to the electrode array for measuring the cell-matrix impedance within the plurality of chambers. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1A -E depicts the configuration of the cell-matrix impedance measurement box with an interdigitated electrode array. Figure 1A Depicted is a substrate 101 having 16 electrode arrays (or 16 electrode structural units) 102 arranged on the substrate in a 2 row by 8 column configuration. Figure 1B is a higher resolution image depicting a single electrode array of a cartridge having two electrode structures 106 , each electrode structure comprising a plurality of interdigitated electrode elements 105 . Figure 1CA schematic diagram of an interdigitated electrode array is shown, illustrating the requirement for a nearly uniform distribution of electrode resistance (by having the same surface area) throughout the array. Figure 1D The configuration of a cell-matrix impedance measurement cassette having a single measurement electrode 107 and a single reference electrode 108 is depicted. Figure 1E An example of a cartridge 200 is shown having a plurality of chambers 210 fluidly coupled to a bioreactor 220 that contains effector cells and delivers the effector cells via a delivery line 230 and an external pump 240. Also shown is a reagent reservoir 225 for containing reagents or media that is connected to a valve 245 for delivery into the chamber 210. Additionally, a gas input 250 and output 260 are shown for delivering CO2 and / or oxygen and / or other gas molecules (as needed for cell culture) into the chamber 210.
[0040] Figure 2 A box with 8 rows of chambers is shown, the chambers are loaded with target cells, the target cells are implemented as cancer cells of different tissue origins, designated as breast cancer (B1-8), lung cancer (L1-8), colon cancer (C1-8), fibrosarcoma (F1-8), prostate cancer (P1-8), kidney cancer (K1-8), epidermal cancer (E1-8), liver cancer (V1-8) and ovarian cancer (O1-8); and the box has three empty columns (Y1-8) for additional cells, which can be added by the operator to perform additional tests. Within each column, different target cells of the same origin are preloaded, such as, but not limited to, different cell lines derived from the same tissue type, different cells with different mutations, different cells with different genotypes, different cells with different gene expressions and / or different protein expressions, etc. Different gene expressions can include genes with different mutations, different overexpressed genes, etc. Different protein expressions can include expressing different protein biomarkers or different target proteins by cells.
[0041] Figure 3 Different approaches to immune-mediated tumor cell killing that can be monitored using cell-matrix impedance technology are shown.
[0042] Figure 4 Real-time monitoring of the proliferation of human non-small cell lung cancer cells (H460 cells) inoculated with different initial cell seeding numbers on a cell-matrix impedance monitoring system is shown. Cell proliferation was recorded continuously, every 15 minutes, for more than 125 hours. Logarithmic scale cell growth curves show cells in exponential cell growth or stationary phase.
[0043] Figure 5Shown is the time-dependent cell index of human non-small cell lung cancer cells (H460 cells) treated with anticancer drug paclitaxel.The culture H460 cells of different chambers are treated with paclitaxel of different concentrations in its exponential growth phase.After treatment, use cell-matrix impedance monitoring system to monitor the dynamic response of cells to different doses of paclitaxel in real time, once every 15 minutes, for 50 hours.For the paclitaxel concentration between 67nM and 500nM, after adding compound, H460 cells initially show a gradual decline in cell index.However, depending on the compound concentration, between about 15 hours to 20 hours after adding compound, cell index reaches minimum value at some time.After this time point, cell index shows that cell index rises gradually.Until about 15 hours after adding compound, the cell index of the compound concentration of 33nM shows a value close to constant.After 15 hours after adding compound, cell index shows that cell index rises gradually.
[0044] Figure 6 The time-dependent cell index of human non-small cell lung cancer cells (H460 cells) treated with the anticancer drug AC101103 is shown. H460 cells cultured in different chambers were treated with different concentrations of AC101103 during their exponential growth phase. The dynamic response of cells to different doses of AC101103 was monitored in real time on a cell-matrix impedance monitoring system every 30 minutes for about 20 hours. Figure 6 Time-dependent cell index and Figure 5 .For the compound concentrations of 3.125 μg / ml, 6.25 μg / ml and 12.5 μg / ml, the cell index shows a value close to constant at about 5 hours, about 15 hours and >20 hours respectively.For the compound concentrations of 3.125 μg / ml and 6.25 μg / ml, the cell index begins to rise after about 5 hours and about 15 hours after adding the compound.For the compound concentration of 25 μg / ml, after adding the compound, the cell index has a gradual and slow decline.For the compound concentration of 50 μg / ml, in the time period of about 10 hours, the cell index remains close to constant, and thereafter, the cell index steadily declines.
[0045] Figure 7 The dynamic drug response curve of adenocarcinoma human alveolar basal epithelial cells (A549 cells) treated with doxorubicin is shown. 10,000 A549 cells are seeded in each chamber of 16X box. Before treatment, cell attachment and cell growth are monitored in real time on the cell-matrix impedance monitoring system of the present invention. When the cell is in the exponential growth phase, doxorubicin of different concentrations is added to the cell. The solvent for dissolving the drug of the same volume is used as a solvent control. The time and drug dose-dependent cell response to doxorubicin are recorded in real time.
[0046] Figure 8 The correlation between the cell number and cell index of NIH 3T3 cells on the cell-matrix impedance monitoring box is shown. The indicated cell number of cells was seeded into essentially Figure 1B A microtiter cassette with an electronic sensor array is shown. The electronic sensor array is pre-coated with fibronectin. Two hours after seeding, the cell index is determined using cell-matrix impedance monitoring.
[0047] Fig. 9A -B shows the response of various cancer cells (listed in Table 1) to doxorubicin treatment monitored using a cell-matrix impedance monitoring system. The indicated cell lines were seeded onto a microtiter box with an electronic sensor array. Cell responses were continuously monitored at time intervals of 15, 30, or 60 minutes before and after treatment with doxorubicin.
[0048] Fig. 10A -B shows the response of various cancer cells (listed in Table 1) to olomoucin treatment monitored using a cell-matrix impedance monitoring system. The indicated cell lines were seeded on a microtiter box with an electronic sensor array. Cell responses were continuously monitored at 15, 30, or 60 minute intervals before and after treatment with olomoucin.
[0049] Fig.11A -B shows the response of various cancer cells (listed in Table 1) to paclitaxel treatment monitored using a cell-matrix impedance monitoring system. The indicated cell lines were seeded on a microtiter box with an electronic sensor array. Cell responses were continuously monitored at 15, 30, or 60 minute intervals before and after treatment with paclitaxel.
[0050] Fig. 12A Shown is the response of human colon adenocarcinoma cells (MV522 cells) to doxorubicin treatment monitored using a cell-matrix impedance monitoring system. MV522 cells were seeded onto a microtiter cartridge with an electronic sensor array and treated with DMSO or doxorubicin for the indicated times and concentrations.
[0051] Fig. 12B Characterization of the cell biological effects of doxorubicin treatment on human colon adenocarcinoma cells (MV522 cells) is shown. Cells were processed using FACS for cell cycle analysis or treated with CFDA and Cy3-Annexin V to assess cell viability. In addition, cells were fixed and stained with phalloidin to examine cell morphology. For viability and morphology, cells were visualized and photographed using a fluorescence microscope equipped with a CCD camera.
[0052] Fig.13AFigure 2 shows the response of adenocarcinoma human alveolar basal epithelial cells (A549 cells) to olomocin treatment monitored using a cell-matrix impedance monitoring system. A549 cells were seeded with Figure 1B The electronic sensor array shown in Figure 2 was mounted on a microtiter cartridge and treated with DMSO or olomouc for the indicated times and concentrations.
[0053] Fig. 13B Characterization of the cell biological effects of olomocin treatment on human colon adenocarcinoma cells (MV522 cells) is shown. Cells were processed using FACS for cell cycle analysis or treated with CFDA and Cy3-Annexin V to assess cell viability. In addition, cells were fixed and stained with phalloidin to examine cell morphology. For viability and morphology, cells were visualized and photographed using a fluorescence microscope equipped with a CCD camera.
[0054] Fig.14A Shown is the response of adenocarcinoma human alveolar basal epithelial cells (A549 cells) to paclitaxel treatment monitored using a cell-matrix impedance monitoring system. A549 cells were seeded onto a microtiter cartridge with an electronic sensor array and treated with DMSO or paclitaxel for the indicated times and concentrations.
[0055] Fig. 14B Characterization of the cell biological effects of paclitaxel treatment on adenocarcinoma human alveolar basal epithelial cells (A549 cells) is shown. Cells were processed using FACS for cell cycle analysis or treated with CFDA and Cy3-Annexin V to assess cell viability. In addition, cells were fixed and stained with phalloidin to examine cell morphology. For viability and morphology, cells were visualized and photographed using a fluorescence microscope equipped with a CCD camera.
[0056] Fig.15A -D is a graph depicting the time-dependent IC values of each compound estimated at 5-hour intervals from the cell index curves obtained using a cell-matrix impedance monitoring system (15A: doxorubicin; 15B: paclitaxel; 15C: olomocin; 15D: tamoxifen) against cancer cell lines, which are recognized lineages of breast, lung, colon, and fibrosarcoma, prostate, epidermal, liver, and ovarian cancers.
[0057] Fig.16A Shown are the cell index curves of human colorectal adenocarcinoma cells (HT29 cells) before and after treatment with doxorubicin, vinblastine or olomocin. Also shown are the theoretical exponential growth of the cell index over time (labeled "logarithmic growth, model") and cells treated with a DMSO vehicle control (labeled "control, HT29").
[0058] Fig. 16BShows from Fig.16A The cell index curves shown are the cell change index (CCI) derived from the cell index curves. Fig. 16C The "black and white shading code" of the rules shown.
[0059] Fig. 16C The color coding scheme used to represent the CCI curve is shown. If DT is the doubling time of the cells undergoing exponential growth in the cell culture medium used, then CCI with different values relative to 0.7 / DT indicates different states of cell change. If CCI>>0.7 / DT, the cells are growing exponentially faster than expected for the exponential growth (or logarithmic growth) of the cells (such areas in the CCI curve are represented by If the CCI is approximately 0.7 / DT, then the rate of cell exponential growth is the same as expected for exponential growth of cells (such an area in the CCI curve is represented by If the CCI is greater than zero but slightly less than 0.7 / DT, the cells are growing exponentially at a rate slower than expected for exponential growth (such an area in the CCI curve is represented by If the CCI is approximately zero, the cell index shows a nearly constant value (such an area in the CCI curve is represented by If the CCI is negative, the cell index is decreasing over time, indicating that the cells have lost their attachment to the electrode surface or have changed their morphology (such areas in the curve are shown as If the CCI is very negative, the cell index decreases rapidly over time, indicating that the cells are rapidly losing attachment to the electrode surface or that the cells are changing their morphology very rapidly (such areas in the CCI curve are represented by rectangle). Transient, fast noise in the CCI values is removed so that after adding the compound, the entire CCI curve is represented by one, two, or three black / white shaded rectangles.
[0060] Fig.17 The cellular response profiles of each cell line tested for the indicated chemotherapeutic agents are shown. For each cell line and compound, the time-dependent cell change index (CCI) was calculated based on its corresponding RT-CES response at the IC50 concentration. (The IC50 is time-dependent, so the IC50 concentration 30 hours after drug addition or the concentration closest to it is used). Fig. 16CThe specific CCI curves associated with specific cellular responses are coded by the rules described in and are displayed in groups of compounds with similar mechanisms of action. DOX: doxorubicin; 5-F: 5-fluorouracil; COL: colcemid; TAXOL: paclitaxel; VIN: vinblastine; OLOM: olomocin; ROS: roscovitine; STAU: staurosporine; TAMO: tamoxifen; RIFA: rifampicin; ACEA-1: ACEA test compound.
[0061] Fig.18 The monitoring of cell proliferation over time of fibrosarcoma cells (H1080 cells), lung cancer cells (H460 cells), hepatosarcoma cancer cells (HepG2) and mouse fibroblast cell line NIH 3T3 after seeding at a density of 2500 and 10,000 cells per chamber of the ACEA 96x E-PLATE box is shown. The cell adhesion, spreading and proliferation were dynamically monitored every 30 minutes using the cell-matrix impedance monitoring system.
[0062] Fig.19 A series of graphs correlating cell-matrix impedance (Cell Index) and the number of cells seeded for comparison of Cell Index using MTT are shown. Fig.19 - In panel A, increasing numbers of NIH 3T3 ranging from 100 cells to 10,000 cells were seeded into the cell-matrix impedance monitoring box and the cells were monitored for 10 hours, at which time points the cell index was obtained. The cell index values were plotted against the corresponding cell numbers. Fig.19 - Panel B, at the end of the experiment, the Fig.19 - cells as described in panel A, and the optical density at 590 nm was plotted against the number of cells seeded.
[0063] Fig. 20A -B depicts the dynamic monitoring of drug-target cell interactions using a cell-matrix impedance monitoring system. Fig. 20A In the experiment, human alveolar basal epithelial cells (A549 cells) were seeded at a density of 10,000 cells per chamber in a cell-matrix monitoring box, and the cells were monitored continuously for 24 hours. Paclitaxel was added at the indicated final concentrations at the 24-hour time point. Fig. 20B A549 cells treated with DMSO or 12.5 nM paclitaxel for 20 hours were stained for Annexin V. Cells were observed with a fluorescence microscope and images were captured with an attached digital camera.
[0064] Fig.21A-B depicts dynamic monitoring of cell cycle arrest using a cell-matrix impedance monitoring system. Human alveolar basal epithelial cells (A549 cells) were seeded at 10,000 cells per chamber in a cell-matrix monitoring box and continuously monitored using RT-CES. Fig.21A )DMSO or 100 μM olomocin were used to treat the cells. Fig. 21B A549 cells grown on tissue culture dishes were treated with DMSO or 100 μM olomocin for 20 h. Cell cycle analysis was performed by flow cytometry.
[0065] Fig. 22 Depicted is the dynamic monitoring of the effects of cytotoxic compounds on target cells using a cell-matrix impedance monitoring system. Human alveolar basal epithelial cells (A549 cells) were seeded in a cell-matrix monitoring cassette and continuously monitored using the RT-CES system. Cells were treated with (A) staurosporine, (B) vinblastine, and (C) 5-fluorouracil at indicated final concentrations.
[0066] Fig.23 Depicts NIH 3T3 cells (target cells) seeded at a density of 20,000 cells / chamber on a microtiter plate (16X E-Plate) of ACEA. The adhesion and proliferation of NIH 3T3 cells were continuously monitored on RT-CES. The cells were allowed to proliferate to the logarithmic growth phase and then treated with effector NK cells at an effector: target ratio of 7.5:1. As a control, target cells were treated with culture medium alone or effector cells lacking killing ability.
[0067] Fig.24 Depicted Fig.23 NIH 3T3 target cells described in the assay were washed, fixed in methanol, and stained with Giemsa blue dye at the end of the assay. The cells were visualized and photographed using an optical microscope connected to a CCD camera. The cytotoxic effect of NK cells (effector cells) on target cells is manifested in the gaps at the bottom of the plate, where cell death has occurred in the target cells due to interaction with the effector cells. The control effector Yac cell line has no gaps and is therefore assessed to have no effect on target cells.
[0068] Fig.25A -B depicts the dynamic monitoring of NK cell-mediated cytolysis on the RT-CES system. Fig.25AIn, dynamic monitoring of NK cell-mediated cell lysis of NIH 3T3 cells (target cells) is shown. NIH 3T3 cells are seeded in a chamber (specifically a hole here) of a 96-well E-PLATE at 5000 cells / chamber, and the attachment, spreading and proliferation of the cells are monitored in real time. 34 hours after cell inoculation, the cell index (CI) value reaches 3, which is approximately equal to 10,000 cells / chamber. 150,000 mNK cells (effector cells) or YAC cells (control effector cells) used as negative controls are added to each chamber in triplicate. Then mNK cell-mediated cell lysis is dynamically monitored. In Fig.25B In Figure 2, the time-dependent cytolytic activity of mNK cells at different ratios of E / T (effector cell number: target cell number) is shown. The cytolytic activity at a given time point was calculated and expressed as a percentage of cytolysis or percentage cytolysis {cytolysis % = (CI 无效应细胞 –CI 效应细胞 ) / CI 无效应细胞 X100}, where CI 效应细胞 and CI 无效应细胞 The cell index of the chamber with and without effector cells added at the time point of interest, respectively. To calculate the percentage of cell lysis shown here, CI uses the normalized cell index value. In general, calculation of percentage cell lysis or percentage cell lysis can use the cell index value or the normalized cell index value.
[0069] Fig.26A -D depicts label-free quantitative measurement of cytolytic activity of mNK cells (murine natural killer cells) and NK 92 cells. Fig.26A In, quantitative measurement of the cytolytic activity of mNK cells is shown. NIH 3T3 cells were inoculated into a 96-chamber E-PLATE. Cell growth was monitored in real time on the RT-CES system until the CI value reached 3, equivalent to 10,000 cells / chamber. mNK cells (effector cells) were added to the target cells at different cell concentrations to make a series of E / T ratios (number of effector cells to number of target cells) as indicated. Cell lysis of target cells at different E / T ratios was dynamically monitored on the RT-CES system. A normalized cell index was used, in which the cell index value obtained after the addition of mNK cells was normalized relative to the cell index value from the same chamber shortly before the addition of mNK cells. In Fig.26B In Figure 2, the time-dependent cytolytic activity of mNK cells at different E / T ratios is shown. The percentage of cytolysis or percentage cytolysis of NIH 3T3 cells by mNK cells was calculated according to the following equation: {% cytolysis = (NCI 无效应细胞 -NCI 效应细胞 ) / NCI 无效应细胞 X100}, where NCI效应细胞 and NCI 无效应细胞 is the normalized cell index of the chamber with and without effector cells added at the time point of interest. Time-dependent cytolytic activity is indicated. Fig.26C In, the quantitative measurement of the cytolytic activity of NK 92 cells is shown. Target cells MCF7 were inoculated as described, and cell growth was monitored on the RT-CES system as described above. NK92 cells were then added to each chamber at different concentrations so that a range of E / T ratios were indicated. The cytolytic activity of NK 92 cells against MCF7 cells at different E / T ratios was dynamically monitored on the RT-CES system. Fig.26D In Figure 2, the time-dependent cytolytic activity of NK92 cells at different E / T ratios is shown. Fig.26B The percentage of cell lysis of MCF7 cells by NK92 cells was calculated and indicated.
[0070] Fig.27A -B depicts label-free assessment of NK cell cytolysis of multiple cell lines on the RT-CES system. Fig.27A NK 92-mediated cytolysis of seven different cancer cell lines is provided. The percentage of cytolysis indicated in each row was calculated based on the Cell Index value of each chamber 8 hours after the addition of NK 92 cells, when the maximum cytolysis was shown. Fig.27B mNK-mediated cytolysis of nine different cell lines is shown. The percentage of cytolysis indicated in each row was calculated based on the Cell Index value of each chamber 12 hours after the addition of NK 92 cells, when maximal cytolysis was exhibited.
[0071] Fig.28 Depicted is the basic principle of the RT-CES system for measuring effector cell-mediated cytolysis of target cells. In Figure A, the interaction of adhered target cells with the sensor microelectrode at the bottom of the chamber results in the generation of an impedance signal, which is expressed in an arbitrary unit called the cell index (CI). In Figure B, the addition of suspended effector cells is not detected by the sensor because these cells do not adhere to the bottom of the chamber. In Figure C, effector cell-mediated cytolysis of target cells is detected by the sensor due to the morphological changes of the target cells and the loss of interaction between the target cells and the microelectrode at the bottom of the chamber after lysis.
[0072] Fig.29A -C depicts RT-CES monitoring of NK-92-mediated cytotoxicity. Fig.29AIn the experiment, 10,000 human alveolar basal epithelial cells (A549 cells) were seeded in the chamber (well) of E-PLATES (Acea Biosciences, Inc., CA). At the indicated time points (arrows), NK-92 cells were added at different E / T ratios, and the viability of A549 cells was dynamically monitored every 15 minutes using the RT-CES system. Fig.29B Depicted is a comparison of RT-CES readout using MTT 25 hours after addition of NK-92 cells. Fig.29A A549 cells were washed as described in , and cell viability was assessed using MTT. For each E / T ratio, the normalized CI values obtained by RT-CES were plotted together with the absorbance values obtained using the MTT assay. Fig.29C In both the RT-CES readout and the MTT assay, the percentage of cytolytic activity of NK-92 cells at different E / T ratios was calculated using the formula as described in the "Materials and Methods" section.
[0073] Fig.30 Depicted is the dynamic monitoring of cytolysis of target cells by mouse NK cells using the RT-CES system. NIH 3T3 cells were seeded in the chamber of the E-PLATE, and mouse NK cells, YAC cells, or culture medium alone were added at different E / T ratios at the indicated time points (arrows). The viability of NIH 3T3 cells was continuously monitored using the RT-CES system.
[0074] Fig.31A -D demonstrates the specificity of NK-92-mediated cytolysis of target cells. Fig.31A ): A549 cells were seeded in the chamber of E-PLATES. Twenty-four hours after seeding NK cells at a density of 16:1 (E / T ratio), they were pre-incubated with different concentrations of the MEK inhibitor PD 98059 for 30 minutes and then added to the A549 cells at the indicated time points (arrows). The viability of A549 cells was continuously monitored using the RT-CES system. ( Fig.31B ): The extent of NK-92-mediated cell lytic activity in the presence of MEK inhibitors was calculated at the indicated times after the addition of NK as described in the Materials and Methods section. Fig.31C ): Effect of PI3 kinase inhibitor wortmannin on NK-92-mediated cytolysis of A549 cells. Fig.31A ) were treated with inhibitors as described in ( Fig.31D ):exist( Fig.31C ) were used to calculate the percentage of cytolytic activity of NK-92 cells.
[0075] Fig.32ADepicted is a graph showing that the addition of EpCAM / CD3 BiTE antibodies (bispecific T cell engagers) promotes PBMC-dependent lysis of PC3 prostate cancer cells. PC3 cells were seeded in E-plate 96 at a density of 10,000 cells / chamber and treated 24 hours later with increasing amounts of EpCAM / CD3 BiTE and freshly isolated PBMCs with an effect / target ratio of 20. PBMCs without BiTEs had no effect (X) on the exponential phase of the PC3 growth curve, while increasing amounts of BiTEs killed cancer cells and induced a decrease in the normalized CI parameter. CI was normalized to the last recorded data point before adding PBMCs.
[0076] Fig.32B PBMC titration is shown demonstrating the high sensitivity of the impedance readout and specificity of cell killing. PC3 cells were treated with 1 μg / ml EpCAM / CD3 BiTE and increasing amounts of effector / target ratio. The figure shows proportionality between ratio and killing kinetics, as well as the effectiveness of a 1:1 ratio.
[0077] Fig.33A -D shows the kinetics of EpCAM BiTE-mediated cell killing in cancer cell lines with different amounts of surface EpCAM protein. Fig.33A Depicted is a flow cytometric analysis of EpCAM surface expression in PC3, MCF7, and HeLa cancer cell lines. EpCAM surface expression in three different cancer cell lines was evaluated using a PE-conjugated anti-human CD326 (EpCAM) antibody (dark gray area). The medium gray shaded area represents the signal of the negative isotype control antibody, and the light gray area represents the autofluorescence of unstained cells. Fig.33B In the study, three cancer cell lines with different EpCAM surface expression levels were seeded at the same density and treated with the same amount of EpCAM / CD3 BiTE antibody and PBMC. The decrease in cell index caused by immune cell-mediated cell killing was proportional to the amount of EpCAM expression in the three cell lines. Fig.33C In , the baseline plot normalizes the CI variation between multiple cell lines and reveals the cell killing efficiency related to antigen expression and the amount of effector cells. The CI of the replicate experiments (1μg / ml EpCAM BiTE) in each group were normalized using the baseline subtraction of the corresponding control group (no PBMC). Gradients of the same color indicate different amounts of PBMC:cancer cell ratios. The thick gray horizontal line corresponds to the no PBMC control used as a baseline. In Fig.33DFigure 5. Effective time to 50% cell killing (ET50) as a function of effector:target ratio for three different cancer cell lines treated with 1 μg / ml EpCAM / CD3 BiTE antibody. Effective time to 50% cell killing (ET50) as a function of effector:target ratio for three different cancer cell lines treated with 1 μg / ml EpCAM / CD3 BiTE antibody.
[0078] Fig.34A ) Daudi B lymphoblasts were plated at a density of 80,000 cells / chamber on chambers coated overnight at 4°C with 1 μg / ml goat anti-human IgM (25 μL). The next day, Tall-104 T lymphoblasts were added at densities corresponding to effector:target ratios of 1.25:1; 0.625:1; 0.313:1; 0.156:1; 0.078:1 and 0.039:1. Fig.34B - Slope plot (A) between time points 4 and 24 after addition of TALL 104. No Tall-104 and the lowest concentration have positive slopes, while the slopes of all other concentration doses are dose-dependently negative. Fig.34C - The Daudi only and Tall-104 only plots show that Tall-104 had a negligible effect on the CI of the IgM coated plates. The Tall-104 plot is reported for the largest amount of Tall-104 (1.25:1) Fig.34C ).
[0079] Fig.35 Results of the study of chambers of the E-PLATE 96 pre-coated with anti-CD40 antibodies (4 μg / mL in PBS; incubated for three hours at room temperature). After washing the chambers with PBS, Daudi B cells were added at a density of 80,000 cells / chamber. 19.9 hours after inoculation of Daudi cells, NK-92 effector cells were added in varying amounts. Impedance was then monitored for an additional 70 hours. Arrows indicate the point at which effector cells were added. (A) Zero NK-92 cells. (B) 80,000 NK-92 cells. (C) 160,000 NK-92 cells. DETAILED DESCRIPTION
[0080] As an introduction, the present invention provides a method for determining the effect of a proposed anticancer therapeutic agent, the means of which is to add the proposed therapeutic agent to a box preloaded with cancer cells, and use cell-matrix impedance monitoring to monitor the cell lysis of cancer cells. The method is suitable for being embodied in various forms of therapeutic agents, such as anticancer compounds that act independently on cancer cells, effector cells, engineered immune cells, oncolytic viruses and combinations thereof. By determining the effect of cell lysis of cancer cells, these methods can further identify treatments suitable for cancer patients. In addition, the cell-matrix monitoring box is suitable for aseptically connecting to a variety of cell culture devices such as bioreactors, thereby reducing the possibility of contamination during the assay. A. Definition
[0081] For clear disclosure, rather than limitation, the detailed description of the present invention is divided into the following subsections. Unless otherwise defined, all technical terms and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs. All patents, applications, published applications and other publications mentioned herein are fully incorporated herein by reference. If the definition set forth in this section is contrary to or otherwise inconsistent with the definition set forth in the patents, applications, published applications and other publications incorporated herein by reference, the definition set forth in this section takes precedence over the definition incorporated herein by reference.
[0082] As used herein, "a" or "an" means "at least one" or "one or more".
[0083] As used herein, a "film" is a sheet of material.
[0084] A chamber surface is "suitable for cell attachment" if a substantial percentage of cells adhere to the chamber surface within twelve hours when a viable, undamaged cancer cell suspension is added to the chamber. Preferably, at least 50% of the cells adhere to the chamber surface within twelve hours. More preferably, a surface suitable for cell attachment has surface properties such that at least 70% of the cells adhere to the surface within twelve hours after plating (i.e., adding the cells to the chamber). More preferably, the surface properties of a surface suitable for cell attachment result in at least 90% of the cells adhering to the surface within twelve hours after plating. Most preferably, the surface properties of a surface suitable for cell attachment result in at least 90% of the cells adhering to the surface within eight, six, four, or two hours after plating. In order to have the desired surface properties for cell attachment, the surface may need to be treated chemically (e.g., with an acid and / or with a base) and / or physically (e.g., with a plasma) and / or biochemically (e.g., coated with one or more molecules or biomolecules that promote cell attachment). In the present invention, the biocompatible surface (such as a membrane) is preferably suitable for the attachment of cells of the type to be used in the assay using the biocompatible surface (such as a membrane), and most preferably, the biocompatible surface allows at least 90% of the cells in contact with the biocompatible surface to attach throughout the assay.
[0085] An "electrode" is a structure with high electrical conductivity, ie, its electrical conductivity is much higher than that of the surrounding material.
[0086] As used herein, "electrode structure" refers to a single electrode, especially an electrode with a complex structure (eg, a spiral electrode structure), or a collection of at least two electrode elements electrically connected together. All electrode elements within an "electrode structure" are in an electrically connected state.
[0087] As used herein, an "electrode element" refers to a single structural feature of an electrode structure, for example, a finger-like protrusion of an interdigitated electrode structure.
[0088] As used herein, an "electrode array" or "electrode structure unit" is two or more electrode structures that are constructed to have such a size and spacing that they can function as a unit when connected to a signal source to generate an electric field in the spatial region around the electrode structure. Preferred electrode structure units of the present invention can measure impedance changes due to cell attachment to the electrode surface. Non-limiting examples of electrode structure units are interdigitated electrode structure units and concentric electrode structure units. In some embodiments, the "electrode array" includes a small measuring electrode and a large reference electrode, the latter directing the impedance measurement value to the small measuring electrode.
[0089] An "electrode bus" is a portion of an electrode that connects separate electrode elements or substructures. The electrode bus provides a common conductive path from separate electrode elements or separate electrode substructures to another electrical connection. In the cartridge of the present invention, the electrode bus may contact each electrode element of the electrode structure and provide an electrical connection path to the electrical traces leading to the connection pads.
[0090] An "electrode trace" or "conductive trace" or "electrical trace" is a conductive path extending from an electrode or electrode element or electrode structure toward one end or border of a box or device for connecting the electrode or electrode element or electrode structure to an impedance analyzer. The end or border of the box may correspond to a connection pad on the box or device.
[0091] A "connection pad" is an area on a device or box of the present invention that is in electrical connection with at least one electrode or all electrode elements within at least one electrode structure on the device or box, and is operably connected to an external circuit (e.g., an impedance measurement circuit or a signal source). The electrical connection between the connection pad and the impedance measurement circuit or signal source may be direct or indirect by any suitable conductive means (such as leads or wires). Such conductive means may also pass through electrodes or conductive paths located in other areas of the device or box.
[0092] "Interdigitated" means that protrusions in one direction are interlaced with protrusions in a different direction, like the fingers of two hands when clasped (it should be noted that the interdigitated electrode elements preferably do not touch each other).
[0093] As used herein, "high probability of contacting electrode elements" means that if cells are randomly positioned within the sensor area of the box or device of the present invention, the probability of the cells (or particles) contacting the electrode elements is greater than about 50%, more preferably greater than about 60%, still more preferably greater than about 70%, even more preferably greater than about 80%, greater than about 90%, or greater than about 95%, calculated based on the average diameter of the cells used on or in the box or device of the present invention, the size of the electrode elements, and the size of the gaps between the electrode elements.
[0094] As used herein, "electrodes [or electrode structures] have substantially the same surface area" means that the surface areas of the plurality of electrodes mentioned do not differ substantially from each other, so that the impedance change caused by cell attachment or growth on any one of the mentioned electrodes (or electrode structures) contributes to the overall detectable change in impedance to the same or similar extent as the impedance change caused by cell attachment or growth on any other mentioned electrode (or electrode structure). In other words, where each electrode (or electrode structure) has substantially the same surface area, any one electrode can affect the overall change in impedance after cells attach to or grow on the electrode. In most cases, the ratio of the surface area between the largest electrode and the smallest electrode having "substantially the same surface area" is less than 10. Preferably, the ratio of the surface area between the largest electrode and the smallest electrode of the electrode array is less than 5, 4, 3, 2, 1.5, 1.2 or 1.1. More preferably, at least two electrodes of the electrode structure have almost the same or the same surface area.
[0095] As used herein, "the box has a surface suitable for cell attachment or growth" means that the electrodes and / or non-electrode areas of the device have appropriate physical, chemical or biological properties so that the cells of interest can be attached to the surface vigorously, and new cells can continue to attach while the cell culture grows on the surface of the device. However, the box or its surface does not necessarily contain substances necessary for cell viability or growth. These necessary substances, such as nutrients or growth factors, can be provided in the culture medium. Preferably, when a suspension of viable undamaged epithelial or endothelial cells is added to the "surface suitable for cell attachment", at least 50% of the cells adhere to the surface within twelve hours. More preferably, the surface suitable for cell attachment has such surface properties that at least 70% of the cells adhere to the surface within twelve hours after plate inoculation (i.e., adding cells to the chamber constituting the box). Even more preferably, the surface properties of the surface suitable for cell attachment allow at least 90% of the cells to adhere to the surface within twelve hours after plate inoculation. Most preferably, the surface properties of the surface suitable for cell attachment result in at least 90% of the cells being attached to the surface within eight, six, four, or two hours after plating.
[0096] As used herein, "detectable impedance change between or among electrodes" (or "detectable impedance change between or among electrode structures") means that when a molecular binding reaction occurs on the electrode surface, the impedance between or among the electrodes (or electrode structures) will undergo a significant change that can be detected by an impedance analyzer or impedance measurement circuit. The impedance change refers to the difference between the impedance value when a molecular binding reaction occurs on the electrode surface of the device and the impedance value when no molecular reaction occurs on the electrode surface. Alternatively, the impedance change refers to the difference between the impedance value when cells are attached to the electrode surface and when the cells are not attached to the electrode surface, or the difference in impedance value when the number, type, activity, adhesion or morphology of cells attached to the electrodes constituting the surface of the device changes. In most cases, an impedance change of greater than 0.1% can be detected. Preferably, the detectable impedance change is greater than 1%, 2%, 5% or 8%. More preferably, the detectable impedance change is greater than 10%. The impedance between or among electrodes is generally a function of the measurement frequency of the applied electric field. "Detectable change in impedance between or among the electrodes" does not require that the impedance change at all frequencies be detectable. "A detectable change in impedance between or among the electrodes" only requires that the impedance change at any single frequency (or multiple frequencies) is detectable. In addition, impedance has two components: resistance and reactance (reactance can be divided into two categories: capacitive reactance and inductive reactance). "A detectable change in impedance between or among the electrodes" only requires that any single frequency or multiple frequencies have a detectable change in either resistance or reactance. In the present application, impedance is electrical impedance or electronic impedance. The method for measuring such impedance is achieved in the following manner: (1) applying a voltage of a given frequency (or multiple frequencies, or having a specific voltage waveform) between or among the electrodes, monitoring the current passing through the electrodes at the frequency (or multiple frequencies, or having a specific waveform), dividing the voltage amplitude by the current amplitude, and obtaining an impedance value; (2) applying a current of a single frequency component (or multiple frequencies or having a specific current waveform) through the electrodes, monitoring the voltage generated between or among the electrodes at the frequency (or multiple frequencies, or having a specific waveform), dividing the voltage amplitude by the current amplitude, and obtaining an impedance value; (3) other methods that can measure or determine electrical impedance. It should be noted that in the above description of "dividing the voltage amplitude by the current amplitude to obtain the impedance value", the "division" is performed using the current amplitude and the voltage amplitude at the same frequency. Such measurement of electrical impedance is an electronic or electrical process and does not involve the use of any reagents.
[0097] As used herein, "the at least two electrodes have substantially different surface areas" means that the surface areas of any electrode are dissimilar to each other, so that the contribution of the impedance change caused by the attachment or growth of cells on the larger electrode to the overall detectable impedance is not the same or similar to the contribution of the impedance change caused by the attachment or growth of cells on the smaller electrode to the overall detectable impedance. Preferably, any impedance change caused by the attachment or growth of cells on the larger electrode is significantly less than the impedance change caused by the attachment or growth of cells on the smaller electrode. Typically, the ratio of the surface area between the largest electrode and the smallest electrode is greater than 10. Preferably, the ratio of the surface area between the largest electrode and the smallest electrode is greater than 20, 30, 40, 50 or 100.
[0098] As used herein, “multiple pairs of electrodes or electrode structures spatially arranged according to the chambers of a multiwell microplate” means that the multiple pairs of electrodes or electrode structures of a box or device are spatially arranged to match the spatial configuration of the chambers of the multiwell microplate so that the box can be inserted, connected or attached to the multiwell microplate (e.g., a bottomless multiwell microplate) when necessary, so that the multiple chambers of the multiwell microplate will include multiple electrodes or electrode structures.
[0099] As used herein, "arranged in a row-column configuration" means that the location of an electrode, electrode array, or switch circuit, in terms of electrical connection, is identified by both a row position number and a column position number.
[0100] As used herein, "each chamber contains substantially the same number of cells..." means that the lowest number of cells in a chamber is at least 50% of the highest number of cells in the chamber. The lowest number of cells in a chamber is at least 60%, 70%, 80%, 90%, 95% or 99% of the highest number of cells in the chamber. More preferably, each chamber contains the same number of cells.
[0101] As used herein, "dose-response curve" represents the dependence of cell response on the dose concentration of the proposed therapeutic compound. Cell response can be measured by many different parameters. For example, the compound is suspected to be cytotoxic and cause cell death. Then, the cell response can be measured by the percentage of non-viable (or viable) cells after the cells are treated with the test compound. This percentage of non-viable (or viable) cells is plotted as a function of the dose concentration of the test compound to construct a dose-response curve. In the present application, the percentage of non-viable (or viable) cells can be expressed as a measured impedance value, or a cell index or cell change index measured from impedance. For example, for a given cell type and under specific cell physiological conditions (e.g., a specific cell culture medium), the cell index can be shown to be linearly correlated or positively correlated with the number of viable cells in the chamber, and the cell index can be derived from the impedance measurement value. Therefore, in the present application, the cell index can be plotted as a function of the dose concentration of the test compound to construct a "dose-response curve". It should be noted that, in general, the cell index is not only related to the number of viable cells in the chamber, but also to cell morphology and cell attachment. Therefore, plotting the cell index against the dose concentration can provide information not only about the number of cells, but also about their physiological state (e.g., cell morphology and cell adhesion). In addition, an important advantage provided by the system and cassette of the present application is that a "dose-response curve" at multiple time points can be obtained in a single experiment, because the system can continuously monitor the cells, providing impedance measurements at many time points in a time range from as short as a few minutes to as long as several days or weeks.
[0102] A "compound" or "proposed therapeutic compound" is any compound whose activity or direct or indirect effect on cells is studied in an assay. A test compound can be any compound, including but not limited to small molecules, macromolecules, molecular complexes, organic molecules, inorganic molecules, biomolecules (such as but not limited to lipids, steroids, carbohydrates, fatty acids, amino acids, peptides, proteins, nucleic acids), or any combination of these substances. A test compound can be a synthetic compound, a naturally occurring compound, a derivative of a naturally occurring compound, etc. The structure of the test compound can be known or unknown. In one application of the present invention, the compound is capable or suspected of inducing cell lysis. In another application of the present invention, the compound is capable or suspected of stimulating effector cells. A "compound" can include two polypeptides linked together to form a bispecific linker, wherein one polypeptide binds to an effector cell (e.g., CD3 on a T cell) and the other polypeptide binds to a target cell, thereby connecting the effector cell to the target cell. In yet another application, the compound is capable or suspected of interacting with a cell (e.g., binding to a cell surface receptor, or inhibiting a certain intracellular signal transduction pathway, or activating a cell).
[0103] A "known compound" is a compound for which at least one activity is known. In the present invention, a known compound is preferably a compound for which one or more direct or indirect effects on cells are known. Preferably, the structure of the known compound is known, but this is not necessarily the case. Preferably, the mechanism of action of the known compound on cells is known, for example, the effect of the known compound on cells may be an effect on cell viability, cell adhesion, apoptosis, cell differentiation, cell proliferation, cell morphology, cell cycle, IgE-mediated cell activation or stimulation, receptor-ligand binding, cell number, cell mass, cell cycle changes, etc., but is not limited to these examples.
[0104] "Impedance value" is the impedance of the electrode in the chamber measured in the presence or absence of cancer cells. Impedance is generally a function of frequency, that is, the impedance value depends on the frequency at which the measurement is performed. For the present application, impedance value refers to the impedance measured at a single frequency or multiple frequencies. In addition, impedance has two components: a resistance component and a reactance component. Impedance value in the present application refers to the resistance component, or the reactance component, or both the resistance component and the reactance component. Therefore, when measuring or monitoring "impedance value", we refer to measuring or monitoring resistance, or reactance, or both resistance and reactance. In many embodiments of the present application method, impedance value also refers to the parameter value obtained from the original measured impedance data. For example, cell index, normalized cell index, or Δ cell index can be used to represent impedance value.
[0105] "Cell Index" or "CI" is a parameter derived from measured impedance values and can be used to reflect changes in impedance values. There are many ways to derive or calculate the Cell Index.
[0106] The "normalized cell index" at a given time point is calculated by dividing the cell index at that time point by the cell index at the reference time point. Thus, at the reference time point, the normalized cell index is 1.
[0107] The "Δ Cell Index" at a given time point is calculated by subtracting the Cell Index at the standard time point from the Cell Index at the given time point. Thus, the Δ Cell Index is the absolute change in Cell Index from the initial time (standard time point) to the measurement time.
[0108] The "Cell Change Index" or "CCI" is a parameter derived from the Cell Index, where the "CCI" at a time point is equal to the first derivative of the Cell Index with respect to time divided by the Cell Index at that time point.
[0109] As used herein, "cytolytic activity" refers to the ability of effector cells to dissolve or kill target cells. For a given ratio of the number of effector cells to the number of target cells and a specific time period after adding effector cells to target cells, if the first type of effector cells kill more target cells than the second type of effector cells, the first type of effector cells has a higher cytolytic activity. Many parameters can be determined and used to indicate or quantify the cytolytic activity of effector cells. For example, the viability of target cells at a certain time point after effector cells are added to the target cells in the chamber can be used to indicate the cytolytic activity of effector cells. The low viability of target cells indicates that many target cells have been killed by effector cells, and indicates that effector cells have high cytolytic activity. In another example, the cytolytic percentage (or percentage of cytolysis) of target cells at a certain time point after effector cells are added to target cells can also be used to indicate cytolytic activity. Low cytolytic percentage indicates that effector cells kill very few target cells, and indicates that effector cells have low cytolytic activity.
[0110] As used herein, "target cell" refers to any cell that can be lysed or killed by an effector cell. The box is preloaded with target cells that are embodied as cancer cells. Non-limiting examples of cancer cells include cancer cell lines and cells isolated from cancer tissue. In an assay for measuring the cytolytic activity of effector cells, it is of interest how many target cells or what percentage of target cells are killed by the effector cells. Therefore, the amount of target cells or the viability of target cells can be determined at any time point during the assay.
[0111] As used herein, the term "lineage" or "cancer cell lineage" refers to the cell line or genotype from which a cancer cell is derived. The term "origin" or "cancer cell origin" refers to the tissue from which the cancer cell arose. The term "stage" refers to the stage of the cancer from which the cell was recovered or obtained.
[0112] As used herein, "effector cell" refers to any cell capable of killing or lysing a target cell, such as natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), neutrophils, eosinophils, macrophages, natural killer T (NKT) cells, B cells, T cells, cell types with cytolytic activity, CAR-T cells and other cells.
[0113] As used herein, "viability" refers to the number or percentage of live cells that are alive or have not yet undergone cell lysis. In an assay for measuring the cytolytic activity of effector cells, it may be necessary to determine the viability of target cells at some time points after effector cells are added to target cells in order to determine how many target cells or how many percent of target cells are killed or dissolved by effector cells. In one embodiment of the method of the present invention, target cells are introduced into a chamber comprising an electrode array, which is used to measure cell-matrix impedance to quantify the number of target cells. Before and after the effector cells are added to the chamber, the impedance of the chamber containing the target cells is measured. In one method, the viability of target cells at a certain time point after the effector cells are added can be determined by comparing the impedance of the chamber before and after the effector cells are added. The viability of target cells can be calculated as the ratio of the impedance of the chamber at the time point of interest to the impedance of the chamber just before the effector cells are added. The implicit assumption of this calculation is that the impedance of the chamber can be roughly proportional to the number of live cells in the chamber. Here, from the time point of adding effector cells to the time point of interest, it is assumed that the target cells have little or no proliferation. Therefore, the ratio of the impedance of the chamber at the time point of interest to the impedance of the chamber just before the effector cells are added reflects the percentage of the initial cells (live cells just before the effector cells are added) that are still alive at the time point of interest. In another method, the viability of the target cells at a certain time point after the effector cells are added can be determined by comparing the cell index of the chamber before and after the effector cells are added. The viability of the target cells can be calculated as the ratio of the cell index of the chamber at the time point of interest to the cell index of the chamber just before the effector cells are added. The implicit assumption of this calculation is that the cell index of the chamber can be roughly proportional to the number of live cells in the chamber. For the calculation of such target cell viability, the cell index can be a normalized cell index. In another method, the target cell viability in the test chamber at a certain time point after the effector cells are added can be determined by comparing the impedance (or cell index) of the chamber at the time point of interest with the impedance (or cell index) of the control chamber, in which the same number of target cells are added without the effector cells. The viability of target cells at a certain time point after the addition of effector cells can be calculated as the ratio of the impedance (or cell index) of the test chamber at the time point of interest to the impedance (or cell index) of the control chamber at the same time point. The implicit assumption of the calculation of target cell viability in such a test chamber is that if the effector cells do not kill or lyse the target cells, the impedance or cell index of the test chamber will be the same as that of the control chamber. For such calculations of target cell viability, the cell index can be a normalized cell index.
[0114] As used herein, "primary cells" refer to any non-immortalized cells that have been derived from various tissues and organs of a patient or an animal.
[0115] As used herein, "cells with cytolytic activity" refers to any cells that are capable of killing or lysing target cells. Cells with cytolytic activity are effector cells.
[0116] As used herein, "antibody-dependent cellular cytotoxicity (ADCC)" refers to the killing of target cells by effector cells (or target cell cytotoxicity), wherein the target cells have been labeled with an antibody. B. Cell-matrix impedance monitoring kit and system
[0117] Cell-matrix impedance monitoring is performed using a cell-matrix impedance monitoring box operably connected to an impedance analyzer. The box has one or more chambers. Each chamber for impedance monitoring has an electrode array at its bottom and is configured to receive cells. When cancer cells are added to the chamber, they attach to the electrode and act as an insulator, thereby increasing the impedance in the chamber. As cells grow and continue to cover the electrode, the current is hindered by the number of cells covering the electrode, the cell morphology and the way of attachment properties. When cancer cells are destroyed, such as when they are destroyed by the presence of compounds (such as toxic compounds, bispecific adapters) and / or immune cells (such as effector cells, CAR-T cells), the accompanying changes in cell morphology and / or attachment change the impedance. Impedance or impedance-based parameters (such as cell index, normalized cell index or cell change index) calculated according to impedance can be plotted over time and used to predict the effect of compounds or immune cells on cancer cell phenotypes. In this way, cell-matrix impedance technology can be used to evaluate potential therapeutic agents, whether compounds or engineered immune cells. Potential therapeutic agents that exhibit anti-cancer activity can then be designated as therapeutic agents for treating the cancer condition and, therefore, administered to a patient.
[0118] The electrode array can be configured in different structural configurations. In some embodiments, the electrode array can follow the array developed by Gaiver and Keese, in which multiple small measuring electrodes share a large reference electrode, and in which the impedance measurement involves the small measuring electrodes. These configurations may be suitable when a large number of cancer cells are added to the chamber or the cells are grown to confluence. In configurations where higher resolution is required (e.g., when fewer than 100 cells are added to the chamber), the electrode array can be configured substantially as Figure 1A -C and the interdigitated electrode array described herein.
[0119] exist Figure 1DAnother high resolution embodiment is shown in , including a single small measuring electrode and a much larger reference electrode. By providing a relatively small measuring electrode, the impedance measurement of the entire array almost entirely involves a single measuring electrode. It has been found that this configuration has extremely high sensitivity and can be used to process very few target cells, such as 10 or less cells, 9 or less cells, 8 or less cells, 7 or less cells, 6 or less cells, 5 or less cells, 4 or less cells, 3 or less cells, 2 or less cells, or a single target cell. When target cells embodied as circulating tumor cells (CTCs) are added to the optional empty chamber of the box, this configuration may be preferred, and circulating tumor cells circulate in very small numbers and are therefore often collected and purified from biological samples in smaller amounts.
[0120] In other embodiments, the electrode array has any suitable shape, for example, a rectangle, a circle, a circle on a rectangular line ("circle on line"), a square on a rectangular line or a sinusoidal line. They can also be in the form of a curve, such as, but not limited to, a spiral or an arc.
[0121] In each configuration, the matrix of the box has a surface suitable for cancer cell attachment and spreading; wherein the attachment or spreading of cells on the matrix results in a detectable change in impedance between or among the electrode structures within each electrode array. It has been shown that cell attachment and extensive spreading of cell populations on the box can result in increased impedance, while dissociation and rolling of cell populations from the box generally decrease impedance. We found that using different chemotoxic compounds, different effector cells, and different cancer cells, the box not only reproducibly detects cancer cell death, but also is able to identify differences in cell-matrix impedance over time, which confirms that the box and system can also be applied to methods for identifying or validating compounds or effector cells with desired anti-tumor activity against specific tumors or cancer cells, thus allowing the cell-matrix impedance monitoring box to be applied to personalized medicine methods.
[0122] In structure, the interdigitated electrode array of two or more electrode structures is constructed to have such size and spacing that they can act as a unit when connected to a signal source, generating an electric field in the spatial region around the electrode structure. As used in this article, "electrode structure" refers to a single electrode, particularly an electrode with a complex structure. For example, the electrode structure can have two or more electrode elements electrically connected together. In a further embodiment, the electrode array has two electrode structures, and each electrode structure has a plurality of electrode elements or substructures. In a preferred embodiment, the electrode structure of each interdigitated electrode array of the box has substantially the same surface area. In a further preferred embodiment, each interdigitated electrode array includes two electrode structures, and each electrode structure has a plurality of electrode elements. Each of the two electrode structures of the electrode array is connected to a separate connection pad located at the edge of the matrix.
[0123] Thus, in some embodiments, for each electrode array, one of the two electrode structures is connected to one of the two or more connection pads, and the other of the two electrode structures is connected to the other of the two or more connection pads. Preferably, each array is individually addressed, meaning that the electrical traces and connection pads of the array are configured so that the array can be connected to an impedance analyzer in a manner such that a measurement voltage can be applied to a single array at a given time using a switch (e.g., an electronic switch).
[0124] Each interdigitated electrode array has an approximately uniform distribution of electrode resistance across the array. By "uniform resistance distribution across the array," it is meant that when a measurement voltage is applied to the electrode structure of the array, the electrode resistance at any given position of the array is approximately equal to the electrode resistance at any other position on the array. Preferably, the electrode resistance at a first position on the array of the box differs from the electrode resistance at a second position on the same array by no more than 30%. More preferably, the electrode resistance at a first position on the array of the box differs from the electrode resistance at a second position on the same array by no more than 15%. Even more preferably, the electrode resistance at a first position on the array of the box differs from the electrode resistance at a second position on the same array by no more than 5%. More preferably, the electrode resistance at a first position on the array of the box differs from the electrode resistance at a second position on the same array by no more than 2%.
[0125] In a preferred interdigital array arrangement, the electrode elements in a given electrode array, the spacing between the electrodes, and the electrode busses are utilized so that all cells, no matter where they land and attach to the electrode surface, contribute similarly to the measured total impedance change of the electrode array. Therefore, it is desirable that within any given array of the box, any two positions have similar electric field strengths when a measurement voltage is applied to the electrode array. At any given position of the interdigital array, the electric field strength is related to the potential difference between the nearest point on the first electrode structure of the array and the nearest point on the second electrode structure of the array. Therefore, it is desirable to have similar potential drops on all electrode elements and on all electrode buses of a given interdigital array. Based on this requirement, it is best to have an approximately uniform distribution of electrode resistance throughout the interdigital array, wherein the electrode resistance at the position of interest is equal to the sum of the electrode resistance between the nearest point on the first electrode structure (i.e., the point closest to the position of interest on the first electrode structure) and the first connection pad connected to the first electrode structure and the electrode resistance between the nearest point on the second electrode structure (i.e., the point closest to the position of interest on the second electrode structure) and the second connection pad connected to the second electrode structure.
[0126] For example, by having electrode structures and electrode buses with specific spacing and dimensions (length, width, thickness, and geometry), a roughly uniform distribution throughout the interdigital array can be achieved, so that the resistance at any single location on the interdigital array is roughly equal to the resistance at any other single location on the interdigital array. In most embodiments, the electrode elements (or electrode structures) of a given interdigital array will have uniform spacing and similar thickness and width, the electrode buses of a given interdigital array will have similar thickness and width, and the electrode traces leading from a given array to the connection pads will have very similar thickness and width. Therefore, in these preferred embodiments, the interdigital array is designed so that the length and geometry of the electrode elements or structures, the length and geometry of the electrode traces, and the length and geometry of the bus allow for an approximately uniform distribution of electrode resistance throughout the array.
[0127] In some preferred embodiments of the cell-matrix impedance measurement box, the electrode structure includes a plurality of electrode elements, and each electrode element is directly connected to an electrode bus. The electrode element of the first electrode structure is connected to the first electrode bus, and the electrode element of the second electrode structure is connected to the second electrode bus. In these embodiments, each of the two electrode buses is connected to a separate connection pad via an electrical trace. Although the resistance of the trace has an impact on the resistance of a certain position on the interdigital array, for any two positions on the array, the trace connection from the first bus to the first connection pad is the same as that from the second bus to the second connection pad. Therefore, in these preferred embodiments, when designing the geometry of the array, in order to provide uniform resistance throughout the array, it is not necessary to consider the trace resistance.
[0128] In some embodiments of each array configuration, the box for monitoring cell-matrix impedance has two or more electrode arrays that share a connection pad. Preferably, one of the electrode structures of at least one electrode array of the box is connected to a connection pad, which is also connected to the electrode structure of at least another electrode array of the box. Preferably, for at least two arrays in the box, each of the two or more arrays has a first electrode structure connected to a connection pad, which is connected to the electrode structure of at least one other electrode array; and each of the two or more arrays has a second electrode structure connected to a connection pad, which is not connected to any other electrode structure or array of the box. Therefore, in the preferred design of the box, there are at least two electrode arrays, each of which has a first electrode structure connected to a common connection pad and a second electrode structure connected to an independent connection pad.
[0129] In some preferred embodiments, each electrode structure of array is connected with electrode bus, and described electrode bus is connected with one of two or more connection pads of box via conductive trace.In preferred embodiments, each in two electrode structures is connected with single bus, makes each array be connected with two buses, and each electrode structure connects a bus.In this arrangement, each in two buses is connected with the independent connection pad of substrate.
[0130] The conductive traces connecting the bus and the connection pads can be made of any conductive material. The traces can be located on the surface of the substrate and can be optionally covered by an insulating layer. Alternatively, the traces can be arranged in the second plane of the substrate. A description of the arrangement and design of the conductive traces on the impedance measurement box can be found in U.S. Patent 7,470,533, and the entire disclosure of the manufacture and design of the conductive traces on the substrate is incorporated herein by reference.
[0131] Appropriate electronic connection means (such as metal clips) bonded to the connection pads on the matrix and the connected printed circuit board can be used to lead electronic connections from the connection pads on the box to external electronic circuits (e.g., an impedance analyzer). A description of the design of a cell-matrix impedance box and its manufacture can be found in U.S. Patent 7,470,533, all descriptions and disclosures of the design, features and manufacture of an impedance box including an electrode array are incorporated herein by reference.
[0132] Preferably, non-conductive matrix is planar, and is flat or approximately flat.Exemplary matrix can be made up of many materials, including but not limited to silicon dioxide on silicon, silicon on insulator (SOI) wafer, glass (for example quartz glass, lead glass or borosilicate glass), sapphire, ceramics, polymer, glass fiber, plastics, for example polyimide (for example Kapton, the polyimide film that DuPont provides), polystyrene, polycarbonate, polyvinyl chloride, polyester, polypropylene and urea resin.Preferably, matrix and matrix surface can not disturb the molecular binding reaction that will occur on matrix surface.For cell-matrix impedance monitoring, any surface that may be exposed to the non-conductive matrix of cancer cell during the use of box of the present invention is preferably biocompatible.Non-biocompatible matrix material can be made to possess biocompatibility by being coated with another kind of material (such as polymer or biomolecule coating).
[0133] All or part of the substrate surface may be chemically treated, including but not limited to, modifying the surface, for example, by adding functional groups or adding charged or hydrophobic groups.
[0134] A description of an electrode array for impedance measurement suitable for use in the box of the present invention is described in U.S. Patent 7,470,533, and all disclosures relating to the electrode array (or structural unit), electrode structure, electrode material, electrode size, and method of manufacturing the electrodes on the substrate are incorporated herein by reference.
[0135] In some preferred boxes, the electrode array is manufactured on a substrate, wherein the array includes two electrode structures, each electrode structure includes a plurality of circular electrode elements on a line, wherein the electrode elements of one structure are alternated with the electrode elements of the relative electrode structure. The interdigitated electrode elements (or electrode structures) of the array of this box of the present invention have approximately equal widths. Preferably, the width of the electrode elements (or electrode structures) of the array of this box of the present invention is greater than 30 microns, more preferably the width is about 50 to about 300 microns, and still more preferably the width is about 90 microns.
[0136] Preferably, the electrode elements (or electrode structures) of the interdigitated array are substantially evenly spaced. Preferably, the gap width between the electrode elements (or electrode structures) of the array of the box of the present invention is less than 50 microns, more preferably about 5 to about 30 microns wide, more preferably about 20 microns wide.
[0137] The box can include one or more fluid-impermeable containers, preferably embodied as chambers, to accommodate fluid. Such containers can be reversibly or irreversibly attached to a matrix or its part, or formed in a matrix or its part (e.g., formed as a chamber in a microtiter plate). In another example, the box includes a microelectrode strip reversibly or irreversibly attached to a plastic shell, and the plastic shell has an opening corresponding to the electrode structure unit on the microelectrode strip. Suitable fluid container materials include plastics, glass or materials coated with plastics, such as ceramics, glass, metal, etc. The description and disclosure of the box including a fluid container can be found in U.S. Patent 7,470,533, and all disclosures of the fluid container and fluid container structure that can engage the matrix including the electrode for impedance measurement are incorporated herein by reference, including its size, design, composition and manufacture method.
[0138] In a preferred embodiment, each electrode array on the matrix of the box is associated with a fluid-impermeable chamber, which can be any suitable container. Preferably, the box is assembled on a bottomless porous plastic plate or strip with a fluid-tight seal. The box is assembled so that the electrode array is at the bottom of the chamber. In some embodiments, the multi-chamber box for cell-matrix impedance measurement has a "non-array" chamber that is attached to the substrate but is not associated with the array. Such a chamber can be optionally used to implement a non-impedance-based mensuration, or for microscopic observation of cells.
[0139] The design and assembly of a multi-chamber impedance measurement box is described in U.S. Pat. No. 7,470,533 and U.S. Pat. No. 7,192,752, the disclosures of which are incorporated herein by reference, including their design, composition and manufacture. The box preferably has 2 to 1,536 chambers, more preferably 4 to 384 chambers, and even more preferably 16 to 96 chambers, wherein all or none of the chambers are associated with an electrode array.
[0140] In some preferred embodiments, commercial tissue culture plates can be refitted to adapt the box. No base plate can also be customized by preferred size. Preferably, the diameter of the chamber is about 1 millimeter to about 20 millimeters at the bottom of the chamber (the end arranged on the matrix), more preferably about 2 millimeters to about 8 millimeters. The chamber can have uniform diameter, or can taper towards the bottom so that the diameter of the container at the end contacting with the matrix is less than the diameter of the opposite end.
[0141] The cassette configurations described in U.S. Pat. No. 7,470,533 and U.S. Pat. No. 7,192,752 typically have a removable lid to allow access to each chamber. To this end, such cassette systems can be preloaded with target cells by pipetting from the top, but more commonly are loaded robotically through the top. Effector cells and / or bispecific adapters are then added by removing the lid and adding the cells or bispecific adapters through the top.
[0142] In other embodiments, the box has a sealed top, which can be sealed before or after pre-loading the target cells. In such an embodiment, a channel system is preferably provided, which is connected to each chamber of the box so that a fluid sample can be delivered to each chamber. Figure 1E An example is shown in FIG. 2 , where a box 200 is shown having multiple chambers 210 accessible via a channel system (dashed lines). Also shown are gas inputs 250 and outputs 260 for transporting oxygen and / or CO2 and / or other gas molecules through the chambers.
[0143] In some embodiments, the channel system includes the same channel divided into sub-channels that share communication with each chamber. As used herein, the term "shared communication" means that the sample delivered to the box is fluidically divided and delivered to each chamber in a group of chambers with "shared communication". When the "shared communication" method is used, it is not necessary (but possible) to deliver equal portions of the incoming sample to each chamber. By using a one-way valve that selectively delivers fluid to the chamber, communication between the chambers themselves can be avoided to prevent contamination. For this reason, shared communication may be preferred when the same sample is added to all chambers simultaneously or nearly simultaneously. For example, it is well known in the art that regular culture medium changes are required to maintain a cell population in culture for a long time, and therefore, a channel system with an inlet that shares communication with each chamber can be used to replace the cell culture medium for all chambers simultaneously or nearly simultaneously. Similarly, such a channel system can deliver gases such as oxygen and / or CO2 to each member chamber. As Figure 1EAs shown, when the effector cells of the same group (provided in the bioreactor 220), such as CAR-T cells, are delivered to each chamber 210, for example, in order to test the CAR-T cells of the same group for a plurality of different target cells preloaded in these chambers, it is also preferred that the same sample be delivered to all chambers. Therefore, the channel system based on shared connectivity better tests the effector cells of the same group and different target cells obtained from the same tissue origin (such as a variety of cell lines derived from the same cancer). Similarly, it can better test the effector cells of the same group and target cells of different cancer stages obtained from the same tissue origin (such as breast tissue). Such a configuration also helps to test the effector cells of the same group and different target cells from different origins (such as across different cancers).
[0144] In some embodiments, the channel system includes one or more channels that selectively deliver samples to less than all chambers. Such a configuration can be accessed by a separate and distinct port along the outside of the box. In another method, the chambers less than all can be selectively entered by the internal fluid sealing valve system in the box, and selective delivery can be achieved by manipulating the system. The internal valve system may include one or more rotary valves, push valves, pull valves, pinch valves, solenoid valves and / or other valves to selectively deliver the same sample to less than all chambers, such as selectively delivering to each chamber or a single group of chambers. In another method, dielectrophoresis or other physical mechanisms can be used as valves to guide or prevent cells (e.g., effector cells) from being delivered to one or more chambers. When testing different effector cells and a group of identical or different target cells, or testing different bispecific linkers and a group of identical or different target cells, selective delivery to less than all chambers may be desirable. Additionally, access to separate chambers may be desirable for providing positive or negative controls for assessing target cell killing.
[0145] In preferred embodiments, the channel system also includes an outlet channel for each chamber so that fluid (e.g., liquid and / or gas) can be removed from each chamber. In some embodiments, the outlet channels merge downstream so that fluid is ultimately removed from all chambers together, but in other embodiments, the outlet channels remain individually distinguishable, such as for collecting supernatant to test for the presence of one or more analytes from separate chambers.
[0146] In some embodiments, the inlet channel for replacing the culture medium is used as the outlet channel for collecting the supernatant from the chamber, and vice versa. Functional switching can allow a complex series of channels to be made at only one end of the cassette; however, such an embodiment may be less preferred for clinical use. In other embodiments, such as Figure 1E As shown, the culture medium may be replaced by connecting the reagent reservoir 225 along a transfer line 230 to a valve 245 to pump the medium into the chamber 210 .
[0147] In a preferred embodiment, the present invention maintains sterility by minimizing contact between the operator and the cultured cells (whether target cells or effector cells). To this end, the box can be loaded (e.g., pipetted) effector cells (and / or bispecific adapters) manually, but preferably loaded without significant exposure to the operator. In embodiments where the box has a removable top, effector cells and / or bispecific adapters can be loaded by removing the top using a robot in a clean environment to reduce the possibility of contamination. In embodiments where the box has a sealed top and a channel system is used to introduce a sample, the channel system can use a suitable pump and / or tubing known in the art to which the present invention belongs to utilize microfluidic flow to transport the sample.
[0148] like Figure 1E As shown, in some embodiments, the effector cells are cultured in a bioreactor 220 and then transported to the cartridge 200 by microfluidic flow. To this end, the cartridge 200 can be provided with suitable tubing 230, connectors, valves 245 and / or pumps 240 to establish fluid communication and transfer. Therefore, the cartridge 200 can be used with any suitable bioreactor 220.
[0149] In some embodiments, the cassette is used in conjunction with a wave swing bioreactor (e.g., a WAVE bioreactor, (GE Healthcare)). The WAVE bioreactor is a disposable system that utilizes non-invasive rocking motion to provide efficient mixing and gas transfer for cell growth. Such a system includes intelligent control software and sensor technology that can be combined with the control system used herein for cell-matrix impedance monitoring.
[0150] When connected to a WAVE bioreactor, the cell-matrix impedance monitoring cassette can be fluidically coupled to a corresponding cell bag (Cellbag) (GE Healthcare) used with the system. By "fluid (ground) coupling" is meant that a fluid, such as a liquid or a gas, can be delivered to the cassette, for example, from a bioreactor to the cassette via a line, pump, and valve configured to transmit the liquid or gas. The Cellbag bioreactor is a subset of the WAVE bioreactor system, in which a pre-sterilized disposable bag is provided, the bag comprising an air inlet, an outlet filter, a needleless sampling port, an oxygen probe insertion port, and a filling / harvesting port. The cell-matrix impedance monitoring cassette can be modified using suitable connectors, transmission lines, microfluidic pumps, and microfluidic valves to fit the harvesting port or sampling port. Any external pumps and valves can be programmed for operation by software within the system of the present invention. In some embodiments, the cell bag itself is further modified with an impedance monitoring electrode array and connected to a cell-matrix impedance monitoring system to assess the growth and viability of effector cells before the effector cells are delivered to the cassette.
[0151] The box itself preferably forms part of a cell-matrix impedance measurement system, which also includes an impedance analyzer, which is electronically connected to the cell-matrix impedance measurement box; a box station (catridgestation), which is capable of engaging one or more boxes and has electronic circuits capable of selecting an electrode array in any one of a plurality of chambers and connecting it to the impedance analyzer; and a software program, which is connected to the box station and the impedance analyzer to control the box station and perform data acquisition and data analysis based on the impedance analyzer.
[0152] In the cell-matrix impedance measurement system, an impedance analyzer engages the connection pads of one or more multi-chamber cartridges to measure impedance. In one embodiment of the above system, the impedance analyzer is capable of measuring impedance between 0.1 ohms and 10 5 The impedance analyzer is preferably capable of measuring both the resistance and reactance (capacitive and inductive) components of impedance. In a preferred embodiment of the above system, the impedance analyzer is capable of measuring the impedance between 0.1 ohms and 10 ohms in the frequency range of 100 Hz to 100 kHz. 3 The impedance between ohms.
[0153] The cell-matrix measurement system can be used to perform multiple assays efficiently and simultaneously by digitally switching the recording from measuring impedance on an array in one chamber to measuring impedance on an array in another chamber using the circuitry of the cartridge station. The resolution of such switching is in the millisecond range and is therefore nearly simultaneous.
[0154] When the box is connected to an impedance analyzer, the difference in impedance values related to cell behavior can be measured. For example, the cell-matrix impedance measurement box can be used to measure the difference in impedance values when cells are attached to an electrode array and when cells are not attached to the electrode array, or can detect the difference in impedance values when the number, type, activity, adhesion or morphology of cells attached to the electrodes constituting the surface of the device changes.
[0155] The cell-matrix impedance monitoring box is preferably maintained by a box station with one or more platforms or one or more slots for locating one or more multi-chamber boxes. One or more platforms or one or more slots may include a socket, a plug or other boxes for electrically connecting the box to the box station. During the cell impedance measurement assay, the box station preferably can be positioned in a tissue culture box. It can be electrically connected to a computer with an impedance analyzer preferably located outside the tissue culture box.
[0156] The box station has an electronic circuit that can be connected to an impedance monitoring box and an impedance analyzer, and an electronic switch that can be connected and disconnected with each electrode array in two or more electrode arrays of the multi-chamber box used in the system. The switch of the box station is controlled by a software program. The software program instructs the box station to connect the array of the box to the impedance analyzer and monitor the impedance from one or more electrode arrays. During impedance monitoring, the impedance analyzer can monitor the impedance of one frequency or more than one frequency. Preferably, for a given assay, impedance monitoring is performed at more than one time point, and preferably, impedance is monitored at at least three time points (including before and after adding effector cells). The box station can connect the array of the box to the impedance analyzer individually to monitor one, some or all arrays of the box at the measurement time point. The switch of the box station allows to monitor selected multiple individual arrays quickly and continuously at each desired monitoring time point. Each monitoring time point is actually a narrow time frame (e.g., from less than one second to several minutes) in the assay, and impedance detection is performed within this time frame. In some preferred embodiments of the present invention, the box station software is programmable to monitor impedance at a given time interval in any chamber of the instruction box including the array.
[0157] The software of the impedance monitoring system can also store and display data. The data can be displayed on a screen and / or as a printed data display. Preferably, the software can allow the input and display of experimental parameters, such as descriptive information, including cell type, compound concentration, monitoring time interval, etc.
[0158] Preferably, the software can also analyze impedance data. In a preferred embodiment, the software can calculate the cell index (CI) of one or more time points for one or more chambers of the multi-chamber box. In some preferred embodiments, the software can calculate the cell change index (CCI) according to the impedance measurement of one or more chambers of the multi-chamber box. The software can preferably generate impedance data and impedance values (such as but not limited to CI or CCI) drawings about time. The software can also perform other analyses, such as calculating cell number from CI, generating dose-response curves based on impedance data, calculating IC values based on impedance values, and calculating kinetic parameters of cell growth or behavior based on impedance values and impedance value curves. The software of the impedance monitoring system can also store and display data analysis, such as calculated impedance values and kinetic parameters obtained therefrom, and the data can be displayed on the screen and / or displayed as printed data. C. Cell Index and Cell Change Index as Comparison Parameters
[0159] In some embodiments, cell-matrix impedance values can be plotted and compared to each other to identify changes in target cell populations. However, based on the dependence between measured impedance, cell number (more precisely, number of live cells or number of attached cells) and cell attachment state, it is possible to derive a so-called "cell number index" or "cell number" from the measured impedance frequency spectrum, which provides a useful index for quantifying and comparing target cell behavior in the impedance-based assay of the present invention. In a preferred embodiment, impedance-based parameters derived from impedance are used for comparison to determine the effect of regulating the target cell population.
[0160] Cell index has been discussed previously. In this application, the term "cell index" is also intended to include "cell number index" as in U.S. Pat. No. 7,470,583, U.S. Pat. No. 7,192,752, and U.S. Pat. No. 7,470,533, each of which is incorporated herein by reference for its discussion and disclosure of cell index and cell number index contained therein.
[0161] The present invention includes several methods for calculating cell index, and the cells are attached to two or more substantially identical arrays of cell-matrix impedance boxes, wherein the impedance changes of cells are monitored in the box. "Substantially identical electrode arrays" or "substantially identical arrays" means that, for a reference array, the size and arrangement of electrodes, electrode structures and electrode elements are the same. Therefore, two substantially identical electrode arrays will have electrode structures of the same size (length, width, thickness), wherein the electrode structures have the same number of electrode elements, and the arrangement of the electrode structures and electrode elements in each array is the same. Arrangement refers to the distance (gap width) between structures or elements, their physical positions relative to each other, and their geometric shapes (angles, curvature degrees, geometric shapes of circles on the line or structures such as cities, etc.), including the same features of any electrode bus that can be connected to electrode structures or electrode elements. Electrodes with substantially identical arrays also include the same material. In order to calculate routing resistance and cell index, matrix can have any number of substantially identical arrays.
[0162] Impedance (Z) has two components, resistance Rs and reactance Xs. Mathematically, impedance Z is expressed as follows:
[0163] Z=Rs+j Xs, (1)
[0164] in It is depicted that for the (series) reactive component Xs, the voltage applied to it is 90 degrees out of phase with the current through it. For a (series) resistor, the voltage applied to it is in phase with the current through it. As is well known in electronics and electrical engineering, impedance can also be expressed in terms of parallel resistance Rp and parallel reactance Xp as follows:
[0165] Z=Rp*(jXp) / (Rp+jXp), (2)
[0166] in However, these expressions (series resistance and series reactance, or parallel resistance and parallel reactance) are equivalent. A person skilled in the art of electrical and electronic engineering can easily derive one form of expression from the values of the parameters in the other expression. For the sake of clarity and consistency, the description and discussion in this invention utilize the expression of series resistance and series reactance. For simplicity, the series resistance and series reactance are simply referred to as resistance and reactance.
[0167] As described in U.S. Patent 7,470,533, wherein the disclosure related to cell-matrix impedance monitoring is incorporated herein by reference, cell-matrix impedance monitoring can be accomplished by measuring impedance in any suitable frequency range to detect or measure impedance changes. For example, impedance can be measured in a frequency range of about 1 Hz to about 100 MHz. In another example, impedance can be measured in a frequency range of about 100 Hz to about 2 MHz. Impedance is generally a function of frequency, that is, impedance values vary with frequency. Cell-matrix impedance can be monitored at a single frequency or at multiple frequencies. If impedance measurement is performed at multiple frequencies, a frequency-dependent impedance spectrum is obtained, that is, impedance values at each measurement frequency. As described above, impedance has two components-resistance component and reactance component. Changes in the resistance component or the reactance component or both can constitute changes in impedance.
[0168] As described in U.S. Pat. No. 7,470,533 (the disclosure of the method for measuring electrical impedance is incorporated herein by reference), the method for measuring electrical (or electronic) impedance is achieved by: (1) applying a voltage of a given frequency (or multiple frequencies, or having a specific voltage waveform) between or among the electrodes, monitoring the current passing through the electrodes at the frequency (or multiple frequencies, or having a specific waveform), and dividing the voltage amplitude by the current amplitude to obtain an impedance value; (2) applying a current of a single frequency component (or multiple frequencies, or having a specific current waveform) through the electrodes, monitoring the voltage generated between or among the electrodes at the frequency (or multiple frequencies, or having a specific waveform), and dividing the voltage amplitude by the current amplitude to obtain an impedance value; (3) other methods that can measure or determine electrical impedance. It should be noted that in the above description of "dividing the voltage amplitude by the current amplitude to obtain an impedance value", "dividing" is performed for the current amplitude and voltage amplitude of the same frequency. As is well known in electrical and electronic engineering, in such calculations (e.g., the division mentioned above), the current magnitude and voltage magnitude are expressed as complex numbers, which take into account the magnitude of the current and voltage and the phase difference between the current and voltage sine waves. Similarly, the impedance value is also expressed in complex form, having both resistive and reactive components, as shown in the above equation.
[0169] As described in U.S. Pat. No. 7,470,533 (incorporated herein by reference for disclosures related to cell index or cell number index), the measured cell-matrix impedance can be used to calculate a parameter referred to as cell index or cell number index. Various methods can be used to calculate such a cell number index based on the change in resistance or reactance when cells are attached to the electrode structure compared to when no cells are attached to the electrode structure. The impedance (resistance and reactance) of an electrode structure with no cells attached to the electrode structure but with the same cell culture medium is sometimes referred to as the baseline impedance. Baseline impedance can be obtained by one or more of the following methods: (1) measuring the impedance of an electrode structure having a cell-free medium, wherein the cell-free medium is introduced into a chamber containing the electrode structure, wherein the medium is the same medium used in impedance measurements for monitoring cell attachment; (2) measuring impedance shortly (e.g., 10 minutes) after applying the cell-containing medium to the chamber including the electrode structure on the bottom of the chamber (there is a short period of time after the cell-containing medium is added so that the cells do not have sufficient time to attach to the electrode surface. The length of this short period of time may depend on the type of cells and / or the surface treatment or modification on the electrode surface); (3) measuring the impedance of the electrode structure when all cells in the chamber are killed by a treatment (e.g., high temperature treatment) and / or reagent (e.g., detergent) (this method is used with the condition that the treatment and / or reagent should not affect the dielectric properties of the medium on the electrode).
[0170] In one example, the cell index or cell number index can be calculated by calculating the resistance ratio by dividing the resistance of the electrode array when cells are present and / or attached to the electrodes by the baseline resistance at each measurement frequency, finding or determining the maximum value of the resistance ratio over the spectrum, and subtracting 1 from the maximum value of the resistance ratio.
[0171] Using the mathematical formula, the cell index is calculated as follows:
[0172]
[0173] Where N is the number of frequency points at which the impedance is measured. For example, if the frequencies used for measurement are 10kHz, 25kHz, and 50kHz, then N = 3, f1 = 10kHz, f2 = 25kHz, and f3 = 50kHz. 细胞 (f i ) is at frequency f i The resistance of the electrode array or electrode structure when cells are present on the electrodes (cell matrix resistance), R b (f i ) is at frequency f i Baseline resistance of the lower electrode array or structure.
[0174] The cell index obtained for a given chamber reflects: 1) how many cells are attached to the electrode surface in the well of this chamber, and 2) the degree to which the cells are attached to the electrode surface in the chamber. In this case, a "cell index or cell number index" of zero or close to zero indicates that no cells or a very small number of cells are present or attached to the electrode surface. In other words, if there are no cells on the electrode, or if the cells are not well attached to the electrode, then R 细胞 (f i ) and R b (f i ) are approximately the same, resulting in a cell index = 0. A higher "cell number index" value indicates that, for cells of the same type and under similar physiological conditions, more cells are attached to the electrode surface. In other words, under the same physiological conditions, the more cells attached to the electrode, the higher the value R 细胞 (f i ) is larger, resulting in a larger Cell Index value. Therefore, the Cell Index is a quantitative measure of the number of cells present in the chamber. A higher "Cell Index" value may also indicate that, for the same type of cells and the same number of cells, the cells are better attached to the electrode surface (e.g., the cells are spread out more, or the cells are more strongly adhered to the electrode surface).
[0175] Therefore, for the same number of cells present in the chamber, changes in cell status will result in changes in the cell index. For example, an increase in cell adhesion or cell spreading results in a large cell / electrode contact area, resulting in an increase in R 细胞 On the other hand, cell death or toxicity induced cell detachment and cell aggregation, resulting in a smaller R 细胞 (f), resulting in a smaller cell index.
[0176] In another example, the cell number index can be calculated by calculating the reactance ratio by dividing the reactance of the electrode array when cells are present and / or attached to the electrodes by the baseline reactance at each measurement frequency, finding or determining the maximum value of the reactance ratio over the frequency spectrum, and subtracting 1 from the maximum value of the reactance ratio.
[0177] In this case, a "cell number index" of zero or close to zero indicates that no cells or very few cells are present or attached to the electrode surface. A higher "cell number index" value indicates that for cells of the same type and under similar physiological conditions, more cells are attached to the electrode surface.
[0178] In yet another example, the cell index can be calculated by subtracting the baseline resistance from the resistance of the electrode array when cells are present or attached to the electrodes at each measurement frequency to determine the change in resistance relative to the baseline resistance when cells are present; and then finding or determining the maximum value of the resistance change.
[0179] In this case, a "cell count index" is derived based on the maximum change in resistance relative to the baseline resistance over the range of measured frequencies when cells are present. This cell index is in ohms. In yet another example, the cell index can be calculated by calculating the magnitude of the impedance (equal to Where R s and X s are series resistance and reactance, respectively); subtract the baseline impedance from the impedance of the electrode array when cells are present or attached to the electrodes to determine the change in impedance relative to the baseline impedance when cells are present; and then find or determine the maximum value of the impedance change.
[0180] In this case, a "cell count index" is derived based on the maximum change in impedance magnitude relative to the baseline impedance over the measured frequency range when cells are present. This cell count index is measured in ohms.
[0181] In yet another example, the index can be calculated as follows: at each measurement frequency, the resistance ratio is calculated by dividing the resistance of the electrode array when cells are present or attached to the electrodes by the baseline resistance; then the relative change in resistance at each measurement frequency is calculated by subtracting 1 from the resistance ratio; and then all relative change values are integrated (i.e., all relative change values at different frequencies are summed).
[0182] In this case, the "cell number index" is derived based on multiple frequency points rather than a single peak frequency as in the above example. Likewise, a "cell number index" of zero or close to zero indicates that no cells are present on the electrode. A higher "cell number index" value indicates that, for cells of the same type and under similar physiological conditions, more cells are attached to the electrode.
[0183] In yet another example, the cell index can be calculated by subtracting the baseline resistance of the electrode array when cells are attached to the electrodes at each measurement frequency to determine the change in resistance relative to the baseline impedance when cells are present; (here, frequency f i The change in resistance under i )=R s-细胞 (f i )=R s-细胞 (f i )-R s-基线 (f i ), R s-细胞 and R s-基线where are the series resistance when the cell is present on the electrode array and the baseline series resistance, respectively); analyzing the frequency dependence of the resistance change to derive certain parameters that can quantify this dependence. In one example, such a parameter can be calculated as In another example, such a parameter can be calculated as The parameter was used as the cell index or cell number index.
[0184] In this case, based on the analysis of the spectrum of the resistance changes, a "cell count index" is derived. Depending on how the parameters are calculated, the cell count index can be measured in ohms. In yet another example, the cell index can be calculated by calculating the magnitude of the impedance (equal to R s and X s are series resistance and reactance, respectively); subtract the baseline impedance from the impedance of the electrode array when cells are attached to the electrodes to determine the change in impedance relative to the baseline impedance when cells are present; (here, frequency f i The change in the impedance is given by ΔZ(f i )=|Z 细胞 (f i )|-|Z 基线 (f i )|Given, R s-细胞 and X s-细胞 are the series resistance and reactance of the cell when it is on the electrode array, respectively, |Z 细胞 (f i )| is the impedance of the electrode array when cells are present on the electrode array, |Z 基线 (f i )| is the magnitude of the baseline impedance of the electrode array); analyzing the frequency dependence of the impedance magnitude change to derive certain parameters that can quantify this dependence. In one example, such a parameter can be calculated as In another example, such a parameter can be calculated as The parameter was used as the cell index or cell number index.
[0185] In this case, a "cell count index" is derived based on analysis of the spectrum of impedance magnitude variations. Depending on how the parameters are calculated, the cell count index can be measured in ohms.
[0186] As described in U.S. Pat. No. 7,470,533, PCT Application No. PCT / US03 / 22557, and U.S. Pat. No. 7,192,752, the disclosure of which is incorporated herein by reference, there are a variety of different methods for calculating a parameter referred to as the cell index or cell number index based on measured cell-matrix impedance (resistance or reactance). The cell index or cell number index is a quantitative measure of cells within a chamber under cell-matrix impedance measurement.
[0187] It is worth pointing out that it is not necessary to derive such a "cell number index" for using impedance information to monitor the cell status on the electrode. In fact, one can choose to directly use the measured impedance (e.g., at a single fixed frequency; or at the maximum relative change frequency, or at multiple frequencies) as an indicator of cell status. If the measured impedance value is used directly to monitor the cell status, resistance or reactance or both resistance and reactance can be used.
[0188] However, there may be advantages to deriving a "cell index" or "cell number index" and using such an index to monitor cell condition. There are several advantages to using a "cell number index" to monitor cell growth and / or attachment and / or viability conditions.
[0189] First, one can use such a cell number index to compare the performance of different electrode geometries.
[0190] Second, for a given electrode geometry, it is possible to construct a "calibration curve" by taking impedance measurements for different numbers of cells added to the electrode to plot the relationship between cell number and the Cell Number Index (in such experiments it is very important to ensure that the seeded cells are well attached to the electrode surface). Using such a calibration curve, when a new impedance measurement is taken, it is then possible to estimate the cell number based on the newly measured Cell Number Index.
[0191] Third, the cell number index can also be used to compare different surface conditions. For the same electrode geometry and the same number of cells, a surface treatment that gives a larger cell number index indicates better cell attachment to the electrode surface and / or a more suitable surface for cell attachment.
[0192] As indicated above, for some methods of calculating cell index or cell number index, it is important to know the impedance (resistance and / or reactance) of the electrode structure with or without cells present on the electrode structure. According to equation (1), the impedance of the electrode array (with or without cells present on the electrodes) is given by:
[0193] Z 电极阵列 =Z 总 -Z 迹线 -Z 开关 (4)
[0194] Where Z 开关 is the impedance of the electronic switch in its on phase, Z 迹线 is the impedance of the electrical connection trace (or conductive trace) on the substrate between the connection pad and the electrode bus, Z 总 is the total impedance measured on an impedance analyzer. By selecting good quality electronic switches, it is possible to have consistent on-impedance (primarily resistance) for all electronic switches. For example, the on-resistance of an electronic switch may be approximately 3 ohms (+ / -10%), while the on-reactance may be negligible (e.g., less than 0.2 ohms over the frequency range of interest). Therefore, if the trace impedance is determined or calculated, equation (4) can be used to calculate the impedance of the electrode array with and without cells present.
[0195] In some embodiments, the parameter used for comparison is the normalized cell index. The "normalized cell index" at a given time point is calculated by dividing the cell index at the time point by the cell index at a reference time point. Therefore, the normalized cell index at the reference time point is 1. The normalized cell index is the cell index normalized to the cell index at a specific time point. In most cases of the present application, the normalized cell index is normalized relative to the time point just before the compound is added or treated. Therefore, the normalized cell index at such a time point (just before the compound is added) is always unity for all chambers. 1 One possible benefit of using such a normalized cell index is to eliminate the effect of differences in cell numbers in different chambers. Chambers with more cells may produce a larger impedance response after compound treatment. Using a normalized cell index helps eliminate this variation caused by different cell numbers.
[0196] The "Δ Cell Index" at a given time point is calculated by subtracting the Cell Index at the standard time point from the Cell Index at the given time point. Thus, the Δ Cell Index is the absolute change in Cell Index from the initial time (standard time point) to the measurement time.
[0197] In some embodiments, "cell change index" is used as a parameter for comparison. Time-dependent cell responses (including cell lysis responses) can be analyzed by deriving parameters that directly reflect changes in cell states. For example, time-dependent cell responses can be analyzed in the following manner: the slope of the measured impedance response change is calculated (equivalent to the first-order derivative of the impedance response with respect to time, where the impedance response can be measured impedance data or derived values, such as cell index, normalized cell index or Δ cell index). In another example, higher-order derivatives of time-dependent cell responses (including cell lysis responses) with respect to time can be analyzed. Such higher-order derivatives can provide additional information about how cells respond to different compounds and the mechanism of action of the compounds.
[0198] As an example, we describe how a parameter called the Cell Change Index can be derived based on the real-time quantitative information provided by the RT-CES system about the biological state of cells in the chamber (i.e., the Cell Index, CI). This new parameter (Cell Change Index (CCI)) can effectively relate the time-dependent Cell Index I to the cell state, and this new parameter is calculated as follows:
[0199]
[0200] Therefore, CCI is the normalized rate of change of the cell index. CCI values can be used to quantitatively describe changes in cell state. For cells that grow exponentially under conventional cell culture conditions, the cell index determined by the cell-matrix impedance monitoring system described herein is expected to be a proportional measure of the number of cells in the chamber, because cell morphology and the average degree of cell adhesion to the electrode surface do not show significant changes over time in the entire cell population. Therefore, the cell index (CI) follows an exponential function that increases over time, such that
[0201]
[0202] where DT is the cell doubling time. For such exponentially growing cultures, CCI(t) is constant, assuming
[0203]
[0204] Therefore, several types of CCI(t) can be classified as:
[0205] If the CCI is approximately 0.7 / DT, then the cell index is increasing at the same rate as expected for exponential growth of the cell.
[0206] If CCI>>0.7 / DT, the cells are growing exponentially faster than expected for exponential (or logarithmic) growth of the cells. This suggests that the cells may be growing faster than normal exponential growth, or that the cells may be exhibiting some morphological changes (e.g., spreading or better adhesion to the electrode surface) that result in a large impedance signal, or both, or that there may be other cellular behaviors that are unique to the assay or culture conditions.
[0207] If the CCI is greater than zero but slightly less than 0.7 / DT, the cells are growing exponentially at a slower rate than expected for exponential growth. This suggests that the cell growth rate may be slowing relative to exponential growth, or that cell growth may be inhibited to some extent by compounds added to the culture medium or other cell culture parameters, or that certain populations of cells are culminating and detaching from the electrode surface, or that there may be other cell behaviors that are unique to the assay or culture conditions.
[0208] If the CCI is approximately zero, the cell index shows a nearly constant value. This may indicate that cell growth is almost completely inhibited. For example, all cells are arrested at some point in the cell cycle and are not progressing further. Alternatively, this may indicate that the number of cells that are dying off in the culture is almost the same as the number of newly dividing cells. Alternatively, this may indicate that the cells have reached the stationary phase of the cell culture. Alternatively, this may indicate that the cell number is above the upper detection limit of the cell-matrix impedance monitoring system. There may also be other cell behaviors that are unique to the assay or culture conditions.
[0209] If the CCI is negative, the Cell Index is decreasing over time, indicating that cells have lost attachment to the electrode surface or have changed their morphology.
[0210] If the CCI is highly negative, the Cell Index decreases rapidly over time, indicating that the cells are rapidly losing attachment to the electrode surface, or that the cells are changing their morphology very rapidly. C. Cell-matrix impedance monitoring of cancer cells
[0211] The cell-matrix impedance monitoring box and system are applied to the method for evaluating the effect of the proposed anticancer therapeutic agent on cancer cells.Such anticancer therapeutic agents can be embodied as compounds, such as bispecific adapters, or cell-based therapeutic agents, such as engineered immune cells (e.g., chimeric antigen receptor T cells (CAR-T cells)). In any case, the proposed anticancer therapeutic agent should be tested on a cell-matrix impedance monitoring box preloaded with target cells (embodied as cancer cells).By providing a box preloaded with cells, the operator can test the effect of anticancer therapeutic agents without maintaining cancer cell culture, and maintaining cancer cell culture may be both time-consuming and technically challenging.In addition, by preloading a group of different lineages, origins or stages of different cancer cells, and by transforming the box to make it suitable for culturing effector cells with a bioreactor, the method can provide effective preliminary screening of the effect of potential therapeutic agents (e.g., engineered immune cells, such as CAR-T cells, bispecific adapters) on different cancer cell groups.
[0212] In one exemplary method, a method for evaluating cytolysis of cancer cells is provided, comprising providing a cell-matrix impedance monitoring box, the box comprising a chamber having an electrode array configured to measure cell-matrix impedance, wherein the chamber is preloaded with target cells embodied as cancer cells; adding effector cells to the chamber to interact with the target cells, wherein the effector cells are immune cells engineered to display a chimeric antigen receptor (CAR) suspected of binding to the target cells; monitoring the cell-matrix impedance of the chamber before and after adding the effector cells, and optionally deriving an impedance-based parameter from the impedance; and determining the killing effect of the effector cells on the target cells by comparing the impedance or the impedance-based parameter over time.
[0213] In another exemplary method, a method for assessing cytolysis of cancer cells is provided, the method comprising providing a cell-matrix impedance monitoring box, the box comprising a chamber preloaded with target cells, wherein the target cells are cancer cells; adding effector cells to the chamber, wherein the effector cells are immune cells; adding a bispecific linker to the chamber, wherein the bispecific linker is a molecule configured to bridge the effector cell to the target cell; monitoring the cell-matrix impedance of the chamber over time, the time including before and after the step of adding the bispecific linker, and optionally deriving an impedance-based parameter from the impedance; and determining the killing effect of the effector cell in response to the bispecific linker by comparing the impedance or the impedance-based parameter over time.
[0214] The various methods of the present invention have a common approach: using cell-matrix impedance monitoring to assess cell lysis, attachment, proliferation and morphological changes of cancer cells in response to the addition of one or more proposed therapeutic agents, whether the therapeutic agent is a compound (e.g., a bispecific linker (BiTe)), a cell (e.g., an engineered CAR-T), or in the form of a virus (oncolytic virus). By providing a cassette preloaded with one or more cancer cells of different lineages, stages, or origins, the specificity or effect on cancers with different characteristics can be determined, and thus the value of the therapy as a treatment for patients can be assessed.
[0215] While the operator could theoretically culture the cancer cells themselves and load them onto the cartridge, in practice it has been found that maintaining multiple different cell cultures may be too time consuming and technically challenging for many end users. To this end, a system has been developed that maintains multiple different cancer cell cultures and provides the cell cultures pre-loaded in a cell-matrix impedance monitoring cartridge that is delivered to the operator or end user in a form that can be assembled onto a bioreactor ready for use in determining cell lysis of cancer cells while maintaining sterility. In addition, since the cartridge itself comes with a cell-matrix impedance measurement electrode array, upon receipt, the operator can assess the viability or state of the cells by engaging the cartridge in the cartridge tray of the impedance system and monitoring the cell-matrix impedance of the culture. Furthermore, by providing an individually addressable electrode array, the impedance-based system can assess the viability and morphology of the cells in each chamber independently of the other chambers.
[0216] Preloaded cancer cells can be primary cancer cells, but in most embodiments, cancer cells are cancer cell lines from the same or different origins. "Origin" means that the cells are derived from the same tissue or the same source. Non-limiting examples of tissues of different origins include breast tissue, lung tissue, colon tissue, mesenchymal cells or fibroblasts (e.g., fibrosarcoma), prostate tissue, kidney tissue, epidermal tissue, liver tissue, and ovarian tissue. In some embodiments, different target cells from the same origin are provided. In such embodiments, target cells belonging to different cell lines or stages, but of the same origin (e.g., different cell lines or different stages of breast cancer) can be preloaded in the box.
[0217] Figure 2 An example of a preloaded plate is shown in , where cancer cells of different origins are arranged in different columns, and different cancer cells of the same origin are arranged in each well within multiple columns. Figure 2 As shown, the non-limiting examples of cancer cells that can be preloaded include cells obtained or derived from one or more cancers, such as breast cancer (B1-8), lung cancer (L1-8), colon cancer (C1-8), fibrosarcoma (F1-8), prostate cancer (P1-8), renal cancer (K1-8), epidermal cancer (E1-8), liver cancer (V1-8) and ovarian cancer (O1-8). Similarly, in each of the above, vertical columns represent different target cells from the same origin. For example, cancer is usually staged according to the order of precancerous state, 0 phase, 1 phase, 2 phase, 3 phase or 4 phase. For this reason, cells derived from the same cancer (such as breast cancer) can be grouped and preloaded according to the stage. That is, the box specific to breast cancer can have a chamber preloaded with cancer cells obtained from each stage, such as precancerous state or 0 phase (B1), 1 phase (B2), 2 phase (B3), 3 phase (B4) and 4 phase (B5).
[0218] In some embodiments, the preloaded cancer cells are cultured and then preloaded into the box within a few days before delivery; however, in a preferred embodiment, the cancer cells are preloaded in the box and cultured for at least one week before delivery to ensure the presence of a reactive culture. It has been found experimentally that it may take several weeks to establish a reactive culture for culturing cancer cells; however, such a time itself is not restrictive for the present invention. After the target cells are added to the chamber, they are allowed to settle on the electrode surface. Cell-matrix impedance monitoring of the cell population can be started when in contact with the electrode surface. As the culture begins to adhere to the electrode and grow, the cells hinder the current in the chamber, and the measured value of the cell-matrix impedance increases. Therefore, although the cells can be visually monitored, for example, by a microscope, it is preferred to consider whether the cells are suitable for delivery electronically by monitoring the cell-matrix impedance. Once the culture in the entire box is considered to be stable and reactive by cell-matrix impedance monitoring, the box can be delivered.
[0219] After receiving the cartridge, the user allows the cells to re-settle on the electrodes prior to use. The cell-matrix measurement feature of the cartridge can be used to determine the status of the cells.
[0220] Once the assay is initiated, impedance is monitored over at least two time points, but often over a number of time points, to establish a baseline impedance, impedance curve, and / or impedance-based curve. The baseline can be compared to determine whether cell lysis occurs after the addition of a proposed therapeutic agent.
[0221] When the therapeutic agent is embodied as engineered effector cells (such as CAR-T cells), the cell-matrix impedance monitoring box can be connected to the culture device accommodating the effector cells.For example, CAR-T cells can be cultured in a bioreactor such as a WAVE bioreactor system (GE Healthcare).In such an embodiment, the cell-matrix impedance monitoring box can be fluidically coupled to the bioreactor so that the effector cells can be delivered to one or more chambers in the box without being exposed to the external environment, thereby maintaining aseptic culture.This is achieved by using an adapter and / or a coupler, and the adapter and / or the coupler attach one end of the transmission line to the bioreactor, and the other end is attached to the box.There are one or more valves and / or pumps between the two ends for regulating the flow of cells entering the box.In another embodiment, the flow between each chamber in the box is regulated by one or more valves or by dielectrophoresis or by other physical mechanisms for controlling the flow of fluid.
[0222] When the therapeutic agent is embodied as a bispecific linker, the effector cells can be delivered in substantially the same manner as described above for the method of CAR-T cell delivery. In addition, the reservoir containing the experimental bispecific linker is fluidically connected to the cell-matrix impedance monitoring box by connecting to the delivery line and pumped into the chamber using a pump.
[0223] In some embodiments, impedance is directly compared over time to assess changes in target cell populations. In other embodiments, impedance-based parameters, such as cell index, cell change index, normalized cell index or cell number, are calculated based on impedance and compared over time. Methods for determining impedance-based parameters are described in detail above. In addition, impedance or impedance-based parameters can be compared at different treatment doses to determine IC50 for comparison between therapeutic agents.
[0224] In some embodiments, the impedance-based parameter is the number of cells (number of viable cells), which can be derived according to the cell index. When determining the effect of the anticancer treatment for cancer cells proposed, it may be useful to determine the number of viable cells. When measuring cancer cell killing, people are usually interested in how many target cells or how many percentages of target cells are killed in response to the therapeutic agent for each lineage, origin or stage, so as to accurately measure its specificity or effect for multiple lineages, origins or stages. Therefore, the number or viability of target cells can be determined using a cell-matrix impedance monitoring system at any time point during the assay. Therefore, in some embodiments, the method includes maintaining target cell counts using cell-matrix impedance monitoring before and after adding the therapeutic agent proposed to determine the percentage of viability or target cell killing percentage. This document provides a method for calculating cell number according to the cell index.
[0225] To demonstrate the applicability of the system for use with target cells embodied as cancer cells, Figure 4 Demonstrated the ability of cell-matrix impedance system to monitor cancer cell proliferation. In this experiment, H460 cells were introduced into the chamber of 16 chamber boxes (16X E-Plate) of the cell-matrix impedance monitoring system, wherein different chambers received different initial cell inoculation amounts. The box was engaged with the box station of the system in the tissue culture incubator, and the incubator maintained a temperature of 37 ° C, and the atmosphere was 5% CO2. Cell-matrix impedance was monitored at intervals of 15 minutes for 125 hours. The system calculates the cell index at each time point, and displays it as a function of time, to provide a cell growth (proliferation) curve for each cell inoculation amount. The cell growth curve is drawn on a logarithmic scale, showing exponential growth phase and stationary phase.
[0226] To demonstrate that dose-dependent changes in cell-matrix impedance can be measured in cancer cells in response to anticancer compounds, Figure 5 The curve representing the time-dependent cell index of H460 cells treated with the anticancer drug paclitaxel of different concentrations is shown. In this experiment, H460 cells are introduced into the chamber of 16X cell-matrix impedance monitoring box (16X E-Plate). The box is placed on the box station in the incubator, and the incubator is kept at 37°C and 5% CO2. Cultivate cells and treat with paclitaxel of different concentrations during its exponential growth period. The dynamic response of cells to different doses of paclitaxel is monitored by using the cell-matrix impedance monitoring system to monitor the cell-matrix impedance in real time after treatment, once every 15 minutes, for 50 hours. The cell-matrix impedance monitoring system calculates the cell index at each monitored time point, and the cell index is plotted as a function of time. For the paclitaxel concentration between 67 nanomoles and 500 nanomoles, after adding the compound, the H460 cells show a gradual decline in the cell index. However, depending on the compound concentration, between about 15 hours to 20 hours after adding the compound, the cell index reaches a minimum at a certain time. After this time point, the cell index of these chambers gradually increased. Until about 15 hours after adding the compound, the cell index of the 33 nanomolar compound concentration showed a nearly constant value. After 15 hours after adding the compound, the cell index showed a gradual increase.
[0227] Figure 6 The curve representing the time-dependent cell index of H460 cells treated with the anticancer drug AC101103 is shown. H460 cells are introduced into the chamber of a 16X cell-matrix impedance monitoring box (16X E-Plate). The box is placed on a box station located in an incubator, and the incubator is maintained at 37°C and 5% CO2. Cells are cultured and treated with different concentrations of AC101103 during their exponential growth phase. The dynamic response of cells to different doses of AC101103 is monitored by measuring impedance in real time on a cell-matrix monitoring system after treatment, once every 30 minutes for 20 hours.
[0228] It is worth noting that Figure 6 Time-dependent cell index and Figure 5.For the compound concentrations of 3.125 micrograms / mL, 6.25 micrograms / mL and 12.5 micrograms / mL, the cell index shows a value close to constant at about 5 hours, about 15 hours and >20 hours respectively.For the compound concentrations of 3.125 micrograms / mL and 6.25 micrograms / mL, after adding the compound for about 5 hours and about 15 hours, the cell index begins to rise.For the compound concentration of 25 micrograms / mL, after adding the compound, the cell index has a gradual and slow decline.For the compound concentration of 50 micrograms / mL, in the time period of about 10 hours, the cell index remains close to constant, and thereafter the cell index steadily declines.
[0229] Figure 7 The dynamic drug response curve of A549 cells treated with doxorubicin is shown. 10,000 A549 cells are seeded in each chamber of 16X box (16X E-Plate). The box is placed on a box station located in an incubator, and the incubator is kept at 37°C and 5% CO2. Before treatment, cell attachment and cell growth are monitored in real time on a cell-matrix impedance system by monitoring impedance at regular intervals. When the cell is in the exponential growth phase, doxorubicin of varying concentrations is added to the chamber. The same volume of solvent for dissolving the drug is added in some chambers as a control. As shown in this figure, the time and drug dose-dependent cell response (calculated as cell index) to doxorubicin is recorded in real time on a cell-matrix impedance monitoring system.
[0230] While the experiments summarized above demonstrate that cell-matrix impedance can be used directly to monitor changes in cancer cell populations in response to administration of anticancer compounds, the present invention also determines cancer cell killing effects in response to the presence of effector cells. Figure 3 Provides an overview of the different effector cells that can be added to the chamber of the cassette to assess cancer cell killing.
[0231] Cell-matrix impedance should be measured before and after effector cells are added to the chamber containing target cells. Since the effector cells are suspended in the chamber, they do not substantially interfere with the sensor electrodes in the chamber. Therefore, impedance changes in response to effector cell addition are almost entirely due to changes in the target cell population.
[0232] Effector cells can be any cells that can kill or dissolve target cells or present or mark target cells (such as by marking the surface of target cells with antibodies) to be lysed by another effector cell. As non-limiting examples, effector cells can be natural killer (NK) cells, cytotoxic T lymphocytes (CTL), neutrophils, eosinophils, macrophages, natural killer T (NKT) cells, B cells, T cells, genetically modified T cells or NK cells and cell types with cytolytic activity. In addition, T cells can be selected from the group consisting of helper T cells (Th cells), cytotoxic T cells and memory T cells.
[0233] Thus, the method provides a method for determining the cytotoxic activity of effector cells against target cells by determining antibody-dependent cellular cytotoxicity (ADCC), bispecific antibody-mediated cytotoxicity, CAR-T-mediated cytotoxicity, complement-mediated cytotoxicity, complement-dependent effector cell-mediated cytotoxicity, and other cytotoxicities that are at least partially dependent on effector cells.
[0234] In some embodiments, the effector cells are further engineered to increase expression of an exogenous compound (such as, but not limited to, interleukin 2) to promote growth, proliferation, or persistence of the effector cells. The effector cells can be added to one or more chambers or fluid containers at a predetermined ratio with the target cells. A person skilled in the art of immunology will be able to provide or determine an appropriate ratio of effector cells to target cells.
[0235] The present invention also provides the addition of compounds or factors that can activate, inactivate or stimulate effector cells. Such compounds may vary due to different effector cells, but may include lipopolysaccharide (LPS), antibodies, auxiliary compounds, compounds obtained or screened from compound libraries, etc. Therefore, the compound or factor can be any suitable compound or factor for stimulating effector cells in the biological field. As a non-limiting example, the compound can be a monoclonal antibody, a polyclonal antibody, a peptide, a protein, a lipid, a biomolecule, a nucleic acid molecule, a naked DNA molecule, etc. A variety of antibodies for the present invention can be obtained or provided, such as but not limited to IgG, IgM, IgE, IgA and heavy chain parts, light chain parts (including κ and λ light chains), Fc parts, Fab parts, Fab'2 parts, etc. The antibody can be humanized or cross-species.
[0236] Similarly, additional cell types or cell lines may be provided as effector cells. Such cells include, but are not limited to, helper cells.
[0237] In some embodiments, a checkpoint inhibitor is added to the chamber to enhance the cancer cell killing effect. The purpose of the checkpoint inhibitor is to break through a major defense of cancer against immune system attack by blocking normal proteins on cancer cells. Examples of checkpoint inhibitors include antibodies or antibody fragments that target PD1, CTLA-4, CD137, OX40, CD27, CD40L, TIM3 on the surface of effector cells, or their corresponding cognate ligands on the surface of target cells.
[0238] Antibody-dependent cell-mediated toxicity (ADCC) is a cell-mediated immune defense mechanism in which effector cells of the immune system actively lyse target cells whose membrane surface antigens have been bound by specific antibodies. In humans, ADCC is usually mediated by IgG. Classical ADCC is mediated by natural killer (NK) cells; however, macrophages, neutrophils, and eosinophils can also mediate it. Because ADCC depends on a previous antibody response, it is part of the adaptive immune response.
[0239] A specific receptor for the constant region of IgG, called FcγRIII, is expressed on the membrane of NK cells and mediates NK cell activation and subsequent ADCC. ADCC is a major component of the anti-tumor activity of antibodies. It is believed that certain tumors carry antigens that can be recognized by the humoral immune system. The subsequent interaction of antibodies with antigens on tumor cells will mark the tumor cells for death by innate immune components such as NK cells.
[0240] Therefore, a method for screening antibody-dependent cellular cytotoxicity (ADCC) is provided, the method comprising providing a cell-matrix impedance monitoring box operably connected to an impedance analyzer, wherein the box comprises a chamber for receiving cells and an electrode array at the bottom of the chamber; adding target cells characterized as cancer cells to the chamber; adding a therapeutic agent that can interact with the target cells to the chamber; adding effector cells to the chamber; monitoring the cell-matrix impedance of the chamber before and after adding the effector cells, and optionally deriving impedance-based parameters from the impedance; and determining the killing effect of the effector cells on the target cells by comparing the impedance or impedance-based parameters over time. The comparison can be a way of comparing the impedance or impedance-based parameters with the same chamber or with a positive or negative control chamber. In some embodiments, the effector cells and the cancer cells are from the same subject. In other embodiments, different cancer cells are preloaded in different chambers. Non-limiting examples of different cancer cells include cancer cells of different lineages, origins, or stages.
[0241] In some embodiments, the proposed therapeutic agent is a bispecific linker. In this way, the step of adding the proposed therapeutic agent can be further characterized as: adding a bispecific linker to a chamber with a target cell to form a test chamber, wherein the bispecific linker is a molecule with a configuration that bridges effector cells to target cells. A bispecific linker refers to two polypeptides connected together, one of which binds to an effector cell or a target cell, and the other peptide binds to the remaining effector cells or target cells, thereby connecting the effector cell to the target cell. Bispecific linkers can be used with macrophages, neutrophils, and eosinophils. However, the bispecific linker is preferably a bispecific T cell linker (BiTe) that binds T cells to cancer cells.
[0242] Thus, a method for assessing cytolytic activity on cancer cells may comprise: providing a cell-matrix impedance monitoring kit comprising different chambers preloaded with different target cells, wherein the different target cells are cancer cells of different lineages, origins or stages; adding effector cells to at least one chamber to form at least one test chamber, wherein the effector cells are immune cells; adding a bispecific linker to the at least one test chamber, wherein the bispecific linker is a molecule having a configuration to bridge the effector cell to the target cell; monitoring the cell-matrix impedance of the at least one test chamber over time, the time including before and after the step of adding the bispecific linker, and optionally deriving an impedance-based parameter from the impedance; and determining the killing effect of the effector cell in response to the bispecific linker by comparing the impedance or the impedance-based parameter over time.
[0243] Exemplary target cells have a cancer cell lineage, cell line or stage derived from one or more cancer origins selected from the group consisting of breast cancer, lung cancer, colon cancer, fibrosarcoma, prostate cancer, kidney cancer, epidermal cancer, liver cancer and ovarian cancer.
[0244] The effector cell can be a natural killer cell (NK cell), a macrophage, a neutrophil, an eosinophil, a T cell or a B cell. When the effector cell is a T cell, the T cell is selected from one or more of the following groups, the composition of the group being: helper T cells (Th cells), cytotoxic T cells and memory T cells.
[0245] In a preferred embodiment, the bispecific linker binds to a T cell surface module (called BiTe), optionally a cluster of differentiation 3 (CD3). BiTe is a modified antibody format with two different domains. One domain recognizes a specific antigen expressed in a target cell (such as a tumor cell), and the other domain recognizes and binds to the CD3 subunit of the T cell receptor complex. By binding to the CD3 subunit, the modified antibody activates immune cells expressing CD3 (such as cytotoxic T lymphocytes) and promotes the destruction of target cells by immune cells.
[0246] In some embodiments, the impedance-based parameter is a cell index, or a normalized cell index normalized to a time point before the addition of the bispecific linker. In some embodiments, the impedance-based parameter is an impedance-based curve, and in further embodiments, the killing effect of the effector cells on the target cells is determined by comparing the impedance-based curve over time. Generally, a reduced impedance or impedance-based parameter indicates an enhanced effect. In a related embodiment, the killing effect of the effector cells on the target cells is determined by calculating and comparing the percentage of cell lysis of the target cells.
[0247] In some embodiments, the assay further comprises monitoring the impedance of the control chamber, whether positive or negative. For example, the method may comprise adding a negative control compound to pre-loaded cancer cells of the same lineage, origin, or stage to form a control chamber in which effector cells are not connected to target cells, monitoring the impedance of the control chamber and optionally deriving an impedance-based parameter based on the impedance of the control chamber; and comparing the impedance or impedance-based parameter between the control chamber and the test chamber over time to determine whether the addition of the bispecific linker enhances the killing of target cells by effector cells.
[0248] In some embodiments, checkpoint inhibitors are added to the chamber to enhance the cancer cell killing effect. The purpose of checkpoint inhibitors is to break through one of the main defenses of cancer against immune system attack by blocking normal proteins on cancer cells. Examples of checkpoint inhibitors include antibodies or antibody fragments targeting PD1, CTLA-4, CD137, OX40, CD27, CD40L, TIM3 on the surface of target effector cells or their corresponding cognate ligands on the surface of target cells.
[0249] In addition, advantages of the present invention include the ability to effectively test adoptive cell transfer therapy methods. Adoptive cell transfer (ACT) is a method that generally involves engineering a patient's own immune cells to recognize and attack tumors and other cancer cells. Although still in clinical trials, many patients' cancer has completely disappeared, and several patients have remained cancer-free for a long time.
[0250] The most common ACT approach involves chimeric antigen receptor (CAR) T cells. CAR-T cells are T cells that have been genetically engineered to produce special receptors (chimeric antigen receptors) on their surface that enable the T cells to recognize specific antigens on tumor cells. These engineered cells are then grown in the laboratory and infused into the patient. The T cells then proliferate in the patient and target cancer cells that display specific antigens.
[0251] Therefore, the present invention provides a method for determining the effect of a proposed adoptive cell transfer (ACT) therapy on cancer cells, which is achieved by: monitoring the cell-matrix impedance of cancer cells in response to the addition of engineered immune cells (such as CAR-T cells); and comparing the impedance or impedance-based parameters (such as cell index, normalized cell index, cell change index, cell number calculated by cell index) measured over time to evaluate the cancer cell killing effect. An exemplary method includes providing a cell-matrix impedance monitoring box operably connected to an impedance analyzer, wherein the box is loaded with target cells, wherein the target cells are cancer cells; adding effector cells to a chamber to form a test chamber, wherein the effector cells are immune cells, and further, wherein the effector cells are engineered to display a binding module suspected of binding to at least some target cells, such as engineered CAR-T cells; monitoring the cell-matrix impedance of the test chamber before and after adding the effector cells, and optionally deriving impedance-based parameters from the impedance; and determining the killing effect of the effector cells by comparing impedance or impedance-based parameters over time. In some embodiments, the target cells are different cancer cells of different lineages, origins, or stages added to different wells. In some embodiments, the effector cells are cultured in a bioreactor and delivered to the target wells by pumping the cell culture through a transfer line.
[0252] Although primarily described with respect to CAR-T cells, the methods described may also be applicable to effector cells such as natural killer cells (NK cells), macrophages, neutrophils, eosinophils, T cells, and B cells.
[0253] Methods for collecting effector cells such as T cells are well known in the art, and generally include purification from blood samples using one or more methods, such as density centrifugation, surface marker detection or binding, flow cytometry sorting and other methods. Cells such as CAR-T cells can be genetically engineered using protocols known in the field of immunology. In a further embodiment, CAR displays a single-chain fragment variable region (scFv) bound to cancer cells. In other embodiments, a single CAR displays multiple scFv regions of different modules (for the same or different proteins) on the surface of the same or different cancer cell lineages. In a further embodiment, scFv is obtained using phage display technology known in the field of immunology. Relatedly, in some embodiments, the method also includes the step of engineering the effector cells to express exogenous proteins, which form part of the CAR.
[0254] In some embodiments, effector cells are engineered to display multiple different CARs that target multiple proteins on the surface of the same or different cancer cells.
[0255] In further embodiments, the effector cells are further engineered to increase expression of an exogenous compound, optionally interleukin 2, to promote growth, proliferation or persistence of the effector cells.
[0256] The method can be used to measure complement-mediated cytotoxicity in the presence of neutrophils or anti-MHC antibodies. The complement system is one of the main effector mechanisms of humoral and innate immunity. Complement proteins bind to tumor cells that have been targeted by IgG and IgM antibodies by interacting with the constant domains of antibodies. The interaction of complement proteins with antibodies on the surface of tumor cells will lead to tumor cell destruction by forming holes on the target cell membrane through components of the complement pathway, or by recruiting neutrophils that engulf tumor cells, or by inducing their destruction through granzymes. Neutrophils contain specific receptors that recognize components of the complement system.
[0257] Therefore, a method for determining complement-mediated cytotoxicity is also provided, the method comprising providing a cell-matrix impedance monitoring box operably connected to an impedance analyzer, wherein the box comprises a chamber loaded with target cells, wherein the target cells are cancer cells; complement and a proposed therapeutic antibody capable of interacting with cancer cells are added to the chamber; the impedance of the chamber is monitored before and after the addition of complement and an impedance-based parameter is optionally derived from the impedance; and the killing effect of the effector cells is determined by comparing the impedance or impedance-based parameters over time. In some embodiments, the target cells are different cancer cells of different lineages, origins or stages preloaded into different chambers. In some embodiments, the effector cells are cultured in a bioreactor and delivered to the target well by means of pumping through a transfer line cell culture. In some embodiments, the proposed therapeutic antibody is pumped from a reagent reservoir into the chamber.
[0258] Oncolytic viruses are another recent class of therapeutic agents that promote anti-tumor responses. As infected cancer cells are damaged by oncolysis, they release new infected virus particles or virions to help destroy the remaining tumors. Oncolytic viruses not only cause direct destruction of tumor cells, but also stimulate the host's anti-tumor immune response. To this end, a method for evaluating cell lytic activity on cancer cells is provided, the method comprising providing a cell-matrix impedance monitoring box operably connected to an impedance analyzer, wherein the box includes a chamber loaded with target cells, wherein the target cells are cancer cells; adding an oncolytic virus to one or more chambers to form one or more test chambers, wherein the virus is suspected of recognizing and dissolving cancer cells; monitoring the cell-matrix impedance of one or more test chambers before and after adding the oncolytic virus, and optionally deriving impedance-based parameters from the impedance; and determining the effect of cancer cell lysis by comparing impedance or impedance-based parameters derived from impedance over time. In some embodiments, the target cells are different cancer cells of different lineages, origins, or stages preloaded into different chambers. In some embodiments, the oncolytic virus is cultured in a bioreactor and delivered to the target well by pumping the virus culture through a transmission line.
[0259] The cancer cells may be derived from one or more cancers, such as breast cancer, lung cancer, colon cancer, fibrosarcoma, prostate cancer, kidney cancer, epidermal cancer, liver cancer, and ovarian cancer.
[0260] Oncolytic viruses themselves do not significantly interact with electrodes, so impedance corresponds to the state of target cells. To this end, impedance-based parameters can be cell indexes, or normalized cell indexes normalized to the time point before adding the virus. Impedance or impedance-based parameters decrease over time indicating enhanced oncolytic activity. Relatedly, impedance-based parameters can be impedance-based curves. In other embodiments, the cancer cell lysis effect is determined by calculating and comparing the cell lysis percentages of target cells. D. Pharmaceutical preparations and medicaments
[0261] Once the proposed therapeutic agent is determined to be effective in killing cancer cells using cell-matrix impedance monitoring technology, it can be formulated into a medicament or pharmaceutical preparation that is ultimately used to treat a cancer patient. In some embodiments, the cancer patient is the same patient from whom the cancer cells are collected. In other embodiments, the cancer patient suffers from the same cancer or the same stage as the cancer cells. One of ordinary skill in the art to which the present invention belongs will recognize that the formulation may depend on the form of the therapeutic agent known in the pharmaceutical field and its route of administration.
[0262] In embodiments where the proposed therapeutic agent is an effector cell, such as a CAR-T cell, the effector cell can be expanded under sterile conditions into a larger population of effector cells, suspended in a saline solution and infused into the bloodstream, or applied surgically for anti-tumor therapy.
[0263] In embodiments where the proposed therapeutic agent is a compound such as a bispecific binding agent, the compound can be combined with pharmaceutically acceptable excipients, carriers, diluents, sweeteners, disintegrants, binders, lubricants, glidants, colorants, flavoring agents, and mixtures thereof, and then administered orally, applied topically, or provided by other routes consistent with the pharmaceutical art for use in cancer treatment.
[0264] Diluents may include, but are not limited to, mannitol, sorbitol, xylitol, microcrystalline cellulose, silicified microcrystalline cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and pullulan.
[0265] Glidants may include, but are not limited to, silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate, magnesium trisilicate, talc, starch, and mixtures thereof.
[0266] Binders may include, but are not limited to, sodium alginate, cellulose, methylcellulose, ethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium hydroxymethylcellulose, polypropylene pyrrolidone, polyvinyl pyrrolidone, gelatin, polyethylene glycol, starch, pregelatinized starch, sugars, trehalose, glucose, tragacanth, sorbitol, gum arabic, alginates, carrageenan, xanthan gum, locust bean gum and gum arabic, waxes, polyacrylamide, and mixtures thereof.
[0267] Lubricants may include, but are not limited to, calcium stearate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, poloxamer, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate, and mixtures thereof.
[0268] Disintegrants may include, but are not limited to, sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, crospovidone, alginic acid, chitosan, methylcellulose, microcrystalline cellulose, powdered cellulose, lower alkyl-substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinized starch, sodium alginate, and mixtures thereof. Example Example 1 Analysis of Cancer Cell Response to Anticancer Drugs Using Cell-Matrix Impedance Monitoring
[0269] In this study, we used cell-matrix impedance monitoring (RT-CES system or xCELLigence RTCA system, ACEA Biosciences, Inc, San Diego, CA) to dynamically monitor the response of cancer cells to mechanistically characterized chemotherapeutic compounds and analyze specific cellular response patterns. Thirteen cancer cell lines were tested, including breast, prostate, lung, colon, ovarian, renal, fibroblastic, and central nervous system cancers (Table 1). Each cancer cell type was treated with 11 chemotherapeutic compounds, which were classified as DNA damaging agents, protein kinase inhibitors, antimitotic drugs, cell cycle-specific inhibitors, protein synthesis inhibitors, and compounds of unknown class (Table 2). The dynamic and dose-dependent cell-compound interaction patterns of all tested cell lines and compounds were characterized and summarized. The profiles of the three drugs doxorubicin, olomocin, and paclitaxel against a group of 12 different cell lines are presented in Figures 9-11, respectively. In addition, we characterized the biological effects of these compounds on cells by monitoring cell cycle progression, cell viability, and the morphological state of cells in an attempt to associate specific cell responses with the shape of the cell index trajectory (Figures 12-14). In addition, we calculated the time-dependent IC-50 values of each compound for various cell lines (Figure 15), and developed an algorithm for calculating the cell change index to analyze the dynamic cell responses of different chemotherapeutic agents to different cell lines. Note that in this application, the RT-CES system refers to the cell-matrix impedance monitoring system. The term RT-CES (real-time cell electronic sensing) is interchangeable with Team RTCA (real-time cell analysis) or xCELLigence RTCA. Both RT-CES and RTCA systems are from ACEA Biosciences Inc. (San Diego CA).
[0270] Using the above definitions, the cellular change index of the dynamic RT-CES (RTCA) response of different cell lines to different chemotherapeutic agents was calculated. Based on the time-dependent values of CCI, each CCI value range across the time scale is represented by a black-white shading-based coding. For example, if after the addition of the compound, the CCI value (for a specific cell line under treatment with a specific compound at a concentration of IC50 value) is close to zero for a certain period of time, and then becomes positive and reaches a value of about 0.7 / DT (DT is doubling); then the cell response to this compound is represented as a Rectangle, followed by a Rectangle. An example of such an analysis is shown in Figure 16. A general coding diagram based on black-white shading showing the dynamic response of cells to different compounds is shown in Figure 16. Fig.17 shown.
[0271] In summarizing this study, we note that screening chemotherapeutic agents using the RT-CES system (or xCELLigence RTCA) yields unique activity patterns depending on the compound, concentration, length of incubation time, and cell type. The “signature” pattern for each drug is associated with specific biological phenomena such as logarithmic growth, cell cycle quiescence, morphological changes, and cell death. The “Cell Change Index” is a well-known parameter derived from RT-CES data that mathematically describes the changes in cells. Analysis of cellular responses based on CCI values showed that drugs with similar mechanisms of action exhibited similar patterns. Therefore, similarities in dynamic cell-compound interaction patterns can indicate similarities in mechanisms of action, modes of antagonism, and possible molecular targets. The RT-CES system can be easily adapted for high-throughput dynamic screening and analysis of anticancer compounds, and the information-intensive approach proposed in this study can be applied to analyze existing cancer chemotherapeutics, screen new compounds, and gain insight into the mechanisms of action of anticancer agents.
[0272] Table 1. List of cancer cell lines tested against various compounds.
[0273] Table 2. List of compounds used in studies analyzing cellular dynamic responses to various anticancer compounds. Example 2 Cytotoxicity assay
[0274] method
[0275] Cells. All cells used in this study were obtained from ATCC and maintained at 37°C in a 5% CO2-saturated incubator. H460, HepG2, and HT1080 cells were maintained in RPMI medium containing 5% FBS and 1% penicillin and streptomycin. NIH 3T3 cells were maintained in DMEM medium containing 10% FBS and 1% penicillin and streptomycin.
[0276] Cell proliferation assay. For each cell type, the indicated number of cells were plated in 96X microtiter plates (e-plate TM ) in each chamber of the box, wherein there is a built-in electrode structure in 100 μL culture medium in a separate chamber of the box. Using the RT-CES system (cell-matrix impedance monitoring system), the attachment, spreading and proliferation of cells are continuously monitored every 30 minutes. Depending on the experiment, cell proliferation is monitored for 48-72 hours. The electronically read cell sensor impedance is displayed as a parameter called cell index.
[0277] Drug treatment and cytotoxicity assessment. For each cell type, the optimal cell concentration was selected based on their respective proliferation patterns ( Fig.18 ). The indicated number of cells was seeded in each chamber of ACEA's 16X or 96X E-Plate (a box for monitoring cell-matrix impedance) in a final volume of 100 μL. Using the RT-CES system (cell-matrix impedance monitoring system), the attachment, spreading and proliferation of cells were continuously monitored every 30 minutes. Approximately 24 hours after inoculation, when the cells were in the logarithmic growth phase, the cells were treated with 100 μL of the indicator compound dissolved in the cell culture medium. The cells were also treated with DMSO for use as a vehicle control. Depending on the experiment, the final DMSO concentration in the culture medium was in the range of 0.25%-0.5%.
[0278] MTT assay. Increasing numbers of NIH 3T3 cells were plated in 16X e-plates and monitored by RT-CES to obtain the corresponding cell index. The medium was immediately aspirated and the cells were assayed using a standard MTT assay according to the manufacturer's protocol.
[0279] Flow cytometry. A549 cells were seeded at a density of 500,000 cells / chamber in 60 mm tissue culture dishes. Approximately 24 hours after seeding, cells were treated with the indicated final concentrations of olomocin, and 16 hours later, cells were washed with PBS, trypsinized, washed twice with PBS and fixed in 70% methanol and stored at 4°C until the staining step. Cells were stained with propidium iodide and analyzed by FACS using a wavelength of 488 nm. Example 3 Real-time monitoring of cancer cell proliferation using RT-CES
[0280] To evaluate dynamic cell proliferation by monitoring cell-matrix impedance using the RT-CES system, H460 human lung cancer cells, H1080 fibrosarcoma cells, HepG2 human hepatic sarcoma cells, and NIH 3T3 mouse fibroblasts were cultured in triplicate on the ACEA 96X e-plate TM 2500 and 10,000 cells were seeded per chamber. Cells were continuously monitored every 30 min for the indicated time using the RT-CES system ( Fig.18 ).like Fig.18 As shown, each cell type has its own characteristic kinetic trajectory based on the number of cells seeded, the overall size and morphology of the cells, and the degree of interaction of the cells with the sensor surface. Furthermore, the adhesion and spreading kinetics, as well as the time for cells to enter the logarithmic growth phase, are characteristic for each identified cell line, thus providing an excellent internal control and providing a way to standardize and validate stock cultures at different stages of the manufacturing process.
[0281] To confirm that the cell index of the RT-CES device correlates with the number of cells in the chamber, increasing numbers of NIH 3T3 cells were plated on 16X e-plates. TM The cells were then monitored for up to 10 hours to obtain the cell index during this period. Fig.19 A shows a plot of the number of cells seeded versus the cell index obtained and indicates that for this particular cell type, the RT-CES system can detect as few as 100 cells and the readout is linear over two orders of magnitude, all the way to 10,000 cells. Fig.19 At the end of the experiment described in A, the cells were also assayed by MTT assay. Fig.19 As shown in B, the MTT assay was not significantly different from background values even up to 1000 cells, and for cell numbers above 1000, the MTT units correlated linearly with the number of cells seeded. However, it is important to note that while the RT-CES system is capable of dynamic and continuous measurements, for comparison reasons, Fig.19 The experiments described in were performed only at a single point, since MTT is a single-point assay. Example 4 Identifying Potential Therapeutic Treatments for Cancer Cells Using the RT-CES Cell-Matrix Impedance Monitoring System
[0282] To evaluate drug efficacy using the RT-CES cell-matrix impedance monitoring system, the IC-50 values of tamoxifen against different cell lines were determined and compared with the MTT assay 48 hours after the addition of tamoxifen. According to Table 3, the IC-50 values of tamoxifen against different cell lines obtained using the RT-CES system were highly consistent with those obtained by the MTT assay, indicating that the RT-CES system can be used to evaluate the efficacy of various drugs against different adherent cell lines.
[0283] To observe the kinetics of drug-target cell interaction, A549 non-small cell lung cancer cells were seeded on ACEA96X e-plate TM The cells were continuously monitored until they reached the logarithmic growth phase, at which time different concentrations of paclitaxel were added to the cells at the indicated final concentrations. Fig. 20A As shown, the highest concentration of paclitaxel initially induced a cytotoxic effect that was primarily due to cell death as judged by annexin V staining ( Fig. 20B ). Remarkably, the cells recovered from the initial cytotoxic effect of the drug and began to re-proliferate. Although it remains to be determined whether this phenomenon is due to the metabolism and inactivation of paclitaxel or the emergence of a paclitaxel-resistant subpopulation, this experiment clearly illustrates the great advantage of real-time measurements provided by this RT-CES system, which gives users the opportunity to observe and evaluate the entire history of drug-target cell interactions, further providing information beyond cell viability or cytotoxicity. If traditional single-point assays such as MTT are used, it is easy to miss Fig. 20A Phenomenon observed in .
[0284] Yet another major advantage of using the RT-CES system to continuously monitor drug interactions with target cells is that the user can gain insight into the mechanism of action of the drug of interest. To demonstrate this, A549 cells were seeded in ACEA96X microtiter cassettes and continuously monitored by RT-CES. Cells were treated with DMSO as a vehicle control or with 100 μM olomocin, a CDK inhibitor that induces cell cycle arrest at either the G→1S transition or the G2→M transition, depending on the cell line. Fig.21A As shown, the addition of olomocin to exponentially growing A549 cells caused the cell index trace of the cells to plateau and remain steady, reminiscent of a cell cycle arrest in which the cells neither proliferate nor die. Control cells treated with DMSO continued to proliferate until they reached confluence, at which point they became contact inhibited and the cell index trace plateaued. To demonstrate that the effects of olomocin on A549 cells monitored by RT-CES were indeed due to cell cycle arrest, A549 cells grown on tissue culture dishes were treated with the same concentrations of DMSO and olomocin and analyzed by flow cytometry. Fig. 21B As shown, flow cytometry analysis showed that treatment of A549 cells with the indicated concentrations of olomocin induced cell cycle arrest at the G2→M transition, when CDKs such as CDK2 are active. In conclusion, the use of the RT-CES system to dynamically monitor the interaction of drugs with target cells provides users with the opportunity to understand the mechanism of action of drugs and how they interact with target cells.
[0285] To evaluate the cytotoxicity analysis of the RT-CES system, the interaction of A549 cells with cytotoxic agents with different mechanisms of action was examined. Fig. 22 Shown by RT-CES TM Characteristic trajectories of A549 cells treated with different concentrations of 5-fluorouracil, vinblastine, and staurosporine were monitored. Fig. 22 By dynamically monitoring the interactions of labeled cytotoxic agents, characteristic kinetic patterns are generated that depend on the cell background, drug concentration, exposure duration, and drug mechanism of action. Since each compound has its own characteristic pattern, these kinetic trajectories are expected to be used to compare the kinetic profiles of compounds with unknown targets with those of compounds with known mechanisms of action, thereby determining the mechanism of action of compounds with unknown targets.
[0286] Compared with traditional endpoint assays, label-free, dynamic monitoring of cell proliferation, viability, and cytotoxicity using the RT-CES system has very obvious and important advantages. It can establish internal quality control to ensure consistency and reproducibility between different assays. Dynamic monitoring can observe the entire process of drug-target cell interaction, so users can better understand the mode and mechanism of drug interaction. In addition, the actual kinetic trajectory of drug-target cell interaction is very important because it can provide clues about the mechanism of drug-target cell interaction. Finally, since each compound or drug has its own characteristic profile in its interaction with target cells, the RT-CES system can be used as a means to determine the mechanism of action of drugs with unknown targets.
[0287] Table 3. uses RT-CES system and the comparison of IC-50 value of tamoxifen treatment of different cancer cell lines of MTT assay.The cell line indicated is inoculated in ACEA 16X box and monitored by RT-CES.After about 24 hours, the cell is treated with tamoxifen of increasing concentration, and then continuously monitored by RT-CES.The experiment is stopped after about 48 hours, and the cell in 16X box (16X E-Plates) is measured by using MTT.The IC-50 value drawn from RT-CES system is time-dependent.In the table, for RT-CES system determination and MTT determination, the IC-50 value of about 48 hours after compound treatment is shown. Table 3 Example 5 NK-mediated killing of NIH 3T3 target cells using the RT-CES cell-matrix impedance monitoring system
[0288] NIH 3T3 cells (target cells) were seeded at a density of 20,000 cells / chamber in the chamber of ACEA's 16X microtiter plate (16X E-Plate). The cells were continuously monitored using RT-CES and allowed to adhere and proliferate overnight. After 18 hours, the cells were incubated with an effector NK cell line at an effector-target ratio of 7.5:1. The target cell response was continuously monitored for the next 24 hours. As a control, the mouse NK cell line Yac, which has insufficient killing ability, was added to the cells at an effector-target ratio of 7.5:1, or only 100 μL of culture medium was added. Fig.23 and 24 As shown, the mouse NK cell line mediated the killing of target cells, as reflected by the decrease in the cell index indicating cell death over time. On the other hand, the control Yac cell line had no significant effect on target cells, even when medium was added alone. This experiment shows that the killing of target cells by effector cells can be monitored in real time using the RT-CES cell-matrix impedance monitoring system. Example 5 Cytolytic activity assay of human and mouse NK cell lines
[0289] Using the RT-CES system, 9 different target cell lines (including cancer cell lines commonly used in the art) were used to test the cytolytic activity of human and mouse NK cell lines. Quantitative and dynamic measurements of NK cell-mediated cytolysis were performed on the RT-CES system without any labeling steps and reagents. The experimental results were consistent. Moreover, the RT-CES system provides real-time fully automatic measurement of cytolysis, thereby providing the possibility for large-scale screening of compounds or genes responsible for regulating NK cell-mediated cytolytic activity.
[0290] Cells. NK 92, NIH 3T3 cell lines and all cancer cell lines used in these experiments were purchased from ATCC. Mouse NK cell line (mNK) was provided by Dr. Hui Shao of the University of Louisville. All cell lines were maintained in an incubator at 37°C with 5% CO2. NK 92 and mNK lines were maintained in Alpha MEM containing 2mM L-glutamine, 1.5g / L sodium bicarbonate, 0.2m inositol, 0.1mM 2-mercaptoethanol, 0.02mM folic acid, 12.5% horse serum, 12.5% FBS and 100-200U / mL recombinant IL-2. Other cancer cell lines were maintained in RPMI medium containing 5% FBS and 1% penicillin and streptomycin (GIBCO). NIH 3T3 cells were maintained in DMEM medium containing 10% FBS and 1% penicillin and streptomycin.
[0291] RT-CES System. The system consists of three components: the analyzer and E-Plate station, integrated software, and a 16-chamber or 96-chamber E-PLATE (16X or 96X E-Plate). The E-Plate station or box station is placed inside the incubator and connected to the analyzer outside the incubator via a thin cable. The E-Plate containing cells is placed on the E-Plate station inside the incubator, and experimental data is automatically collected by the analyzer under the control of the integrated software.
[0292] Cell Lysis Assay. Target cells are seeded into 100 μl of medium in a chamber of a 16- or 96-chamber E-Plate. Using the RT-CES system, cell growth is dynamically monitored for 24-34 hours, depending on the experiment, until they reach logarithmic growth phase and form a monolayer. Effector cells at varying concentrations are then added directly to a separate chamber containing target cells. For background control, effector cells are added to a chamber without target cells. After the addition of effector cells, the E-Plate is returned to the E-Plate Station and measurements are automatically collected by the analyzer every 15 minutes for up to 20 hours.
[0293] Analysis of cell morphology by microscopy. The effect of NK cell-mediated cytolysis on target cells was examined using a Nikon upright microscope. After the addition of effector cells, when the cell index reached 50% of the control, the cells were fixed in 80% methanol for 5 minutes and then stained with Giemsa blue. The morphology of the cells was examined by microscopy and photographed using an attached CCD camera.
[0294] Experimental data analysis. The integrated software can display the entire process of the experiment from cell inoculation to the end of cell lysis. The time and effect-target ratio (E / T) dependence curves can be displayed in real time, thus providing the possibility of dynamic monitoring of NK cell activity. The electronically read cell-electrode impedance is displayed as a dimensionless parameter called the cell index. The cell index here is determined as follows: For each measurement frequency f, the resistance (a component of the impedance) of the chamber when the target cells are present in the chamber is calculated (R 细胞 (f) Relative to the background resistance of the chamber when there are no cells but only cell culture medium in the chamber (R 背景 Relative change (f) = (R 细胞 (f)-R 背景 (f)) / R 背景 (f)), then the maximum relative change in resistance for all measured frequencies was found (cell index = max{relative change (f)} for all measured frequencies. The maximum relative change in resistance was used as the cell index. To quantitatively determine lysis at a specific time point, the cell index data was exported from the RT-CES software to Microsoft Excel, and the percentage of cell lysis at a specific E / T ratio at a given time was determined by comparing the cell index of the chamber with a specific E / T ratio with the cell index of the control chamber without NK cells added and calculating using the following equation: Cell lysis percentage = (1-CI 给定E / T比 / CI 没有NK细胞 ) x 100. Fig.25B , 26B Normalized cell index values were used in the calculation of the percentage of cell lysis in 26D, 27A, and 27B.
[0295] Results and Discussion: Dynamic Monitoring of NK Cell-Mediated Cytolysis. In order to evaluate NK cell-mediated cytolytic activity using the RT-CES system, mouse NK cell lines (mNK cell lines) and target cell lines NIH 3T3 cells were used. NIH 3T3 target cells were seeded in the chamber of a 96-chamber E-Plate at 5000 cells / chamber, and cell growth was continuously monitored on the RT-CES system every 60 minutes until the cells reached the growth phase after 34 hours. Effector mouse NK cells were then added directly to the chamber at different E / T ratios, and NK cell-mediated cytolysis was dynamically monitored on the RT-CES system. As shown in Figure 25a, after adding mNK cells at an E / T ratio of 15 to 1, a significant decrease in the cell index of NIH 3T3 cells was observed compared to the cell index of the culture medium control. Furthermore, no significant decrease in cell index was observed in the effector control chamber using YAC cells (a T lymphocyte line without cytolytic activity), indicating that the decrease in cell index due to the addition of mNK cells was specific and most likely mediated through cytolysis. Time-dependent cytolysis of NIH 3T3 cells was also observed in the presence of mNK cells, but not in the presence of YAC cells ( Fig.25B ). To further confirm the cytolysis, the target cells were stained 8 hours after adding mNK cells to the target cells, at which time the cells were lysed by about 50%, and then examined under a microscope (data not shown). Compared with the control YAC cells, in the presence of mNK cells, the target cells were effectively cleared by the cytolysis of mNK. In summary, the RT-CES system provides the only direct monitoring of NK cell-mediated cytolysis so far, without the need to label target cells and use any chemical reporter assay format. In addition, the entire process of cell lysis can be dynamically monitored on the RT-CES system, which is difficult to implement by any marker-based endpoint assay format. Cytolysis kinetic analysis showed that slow cell lysis was detected for mNK cells. Cell lysis was detected within 2 hours of adding mNK cells, and interestingly, only less than 30% of cell lysis activity was detected after 4 hours. The four-hour incubation time is the standard incubation time based on the radioisotope endpoint assay. The data obtained by the RT-CES system clearly show that the cell lysis activity can reach 70%, which occurs 12 hours after adding mNK cells. In existing marker-based endpoint assays, this cytolytic activity that occurs after the standard incubation time of the assay may be easily missed. Therefore, the RT-CES system not only provides label-free detection, but more importantly, it provides the possibility of more accurate assessment of cytolytic activity by dynamically monitoring the entire process of cell lysis. Example 6 Quantitative measurement of NK cell-mediated cell lysis
[0296] The cell index readout of the RT-CES system is related to the cell number (Solly et al., 2004) and is used to quantitatively monitor the cytotoxicity induced by compounds such as anticancer drugs. In order to test whether mNK cell activity can be quantitatively measured in the RT-CES system, we monitored cell lysis at different effector / target ratios. Both mouse and human NK cell lines (mNK and NK 92) were used as effector cells, and the NIH 3T3 line and MCF7 line (human breast cancer cells) were used as target cells for each effector cell, respectively. As described above, the target cells were first seeded on a 96-chamber E-Plate at 5,000 cells / chamber, and then cell growth was monitored on the RT-CES system. When the target cells reached the growth phase, NK cells were added directly to the chamber at different concentrations. NK cell-mediated cell lysis at different E / T ratios was then monitored in real time on the RT-CES system. Fig.26A and 26C As shown in Figure 2, after mNK or NK 92 cells were added to their target cells, the cell index decreased compared to the control without effector cells. The decrease in cell index value was dependent on the E / T ratio. In either case ( Fig.26A NIH 3T3 cells, Fig.26C The higher the E / T ratio, the lower the cell index value obtained. This strongly indicates that the RT-CES system is able to specifically and quantitatively measure NK cell-mediated cytolytic activity. Moreover, dynamic monitoring of cell lysis can further reveal the underlying mechanisms of NK cell-mediated killing. For example, cell lysis kinetic analysis showed that NK 92 cells are much more potent effector cells than mNK cells. At an E / T ratio of 4 / 1 or higher, greater than 90% MCF7 cell lysis (100% NK cell lysis) can be achieved within 4 hours after adding NK 92 cells. Fig.26D ), while mNK cells only had about 30% (Figure 26b). The different cytolytic kinetics of NK cells indicate the unique nature of the interaction between effector cells and target cells (such as the expression of NK receptors and ligands) and the basic mechanism of NK cell-mediated cytolysis.
[0297] Label-free evaluation of NK cell cytolytic activity in various target cell lines on the RT-CES system. The cytolytic activity of mNK and NK 92 was tested using 9 cell lines, including 8 different human cancer cell lines and the NIH 3T3 cell line. Tables 4 and 5 summarize the sensitivity of different target cell lines to mNK or NK 92-mediated cytolysis. NK 92 showed a wide range of cytolytic activity on cancer cell lines. NK 92-mediated cytolysis occurred rapidly and reached maximum killing activity before 8 hours after the addition of NK 92 cells. Fig.27AThe comparison of the sensitivity of 7 cancer cell lines to NK 92 cells is shown in Figure 1. Among these 7 cancer target cell lines, 4 target cell lines achieved more than 90% cell lysis, including H460, HepG2, MCF7, and MDA-MB231. In contrast, mNK cell-mediated cell lysis appears to be more selective than NK92 ( Fig.27B ). Among the 9 target cell lines, 4 target cell lines, including NIH 3T3, A549, Hela and MDA-MB231, showed more than 30% cell lysis after incubation with mNK cells for 12 hours, while no cell lysis (0%) or weak cell lysis (10%) was found in 5 target cell lines, including OVCR4, HT1080, HepG2, H460 and MCF7. In addition, the cell lysis mediated by mNK was much slower than that of NK 92, reaching the maximum value 12 hours after the addition of mNK cells. Table 4. mNK cell-mediated cytolysis of 9 cell lines Table 5. Cytolysis of 7 cell lines mediated by NK 92 cells Example 7 Dynamic label-free monitoring of natural killer cell-mediated cytolysis of target cells using cell-matrix impedance monitoring.
[0298] In this embodiment, the RT-CES cell-matrix impedance monitoring system provides a label-free assessment of the cytolytic activity mediated by natural killer (NK) cells. The cytolysis of 9 different target cell lines mediated by NK is dynamically and quantitatively monitored using the RT-CES system, including the cancer cell line commonly used as a cancer model in the laboratory. The cytolysis monitored by the RT-CES system is compared with standard techniques (such as MTT measurements), showing good correlation and better sensitivity. In order to test the specificity of the assay, a pharmacological agent that inhibits NK cell degranulation and cytolysis is used, showing selectivity and dose-dependent inhibition of the cytolysis of NK-mediated target cells. In a word, the RT-CES system can provide a real-time fully automatic measurement of cytolysis, thereby providing possibility for large-scale screening of compounds or genes responsible for regulating the cytolytic activity of NK mediation.
[0299] Cells. NK 92, NIH 3T3 cell lines and all cancer cell lines used in these experiments were purchased from ATCC. Mouse NK cell line (mNK) was provided by Dr. Hui Shao of the University of Louisville. All cell lines were maintained in an incubator at 37°C with 5% CO2. NK 92 and mNK lines were maintained in Alpha MEM containing 2mM L-glutamine, 1.5g / L sodium bicarbonate, 0.2m inositol, 0.1mM 2-mercaptoethanol, 0.02mM folic acid, 12.5% horse serum, 12.5% FBS and 100-200U / mL recombinant IL-2. Other cancer cell lines were maintained in RPMI medium containing 5% FBS and 1% penicillin and streptomycin (GIBCO). NIH 3T3 cells were maintained in DMEM medium containing 10% FBS and 1% penicillin and streptomycin.
[0300] RT-CES system. The system consists of three components: the analyzer and E-plate station, integrated software, and 16- or 96-chamber E-plates. The E-plate station is placed inside the incubator and connected to the analyzer outside the incubator via a thin cable. The E-plate containing cells is placed on the E-plate station inside the incubator, and experimental data are automatically collected by the analyzer under the control of the integrated software. The principles of RT-CES technology have been described previously (Abassi et al., 2004; Solly et al., 2004; Xing et al., 2005).
[0301] Cell Lysis Assay. Target cells are seeded into 100 μL of culture medium in the chambers of a 16- or 96-chamber E-plate. Using the RT-CES system, cell growth is dynamically monitored for 24-34 hours, depending on the experiment, until they reach logarithmic growth phase and form a monolayer. Effector cells at varying concentrations are then added directly to a separate chamber containing target cells. To set up a background control, effector cells are added to a chamber without target cells. After the addition of effector cells, the E-Plate is placed back into the E-plate station and measurements are automatically collected by the analyzer every 15 minutes for up to 20 hours.
[0302] Analysis of cell morphology by microscopy. The effect of NK cell-mediated cytolysis on target cells was examined using a Nikon upright microscope. After the addition of effector cells, when the cell index reached 50% of the control, the cells were fixed in 80% methanol for 5 minutes and then stained with Giemsa blue. The morphology of the cells was examined by microscopy and photographed using an attached CCD camera.
[0303] Data Analysis. The integrated software is able to display the entire course of the experiment from cell inoculation to the termination of cell lysis. Time and effector-to-target ratio (E / T) dependence curves can be displayed in real time, allowing dynamic monitoring of NK cell activity. The electronically read-out cell-electrode impedance is displayed as a dimensionless parameter called the cell index. The cell index is determined here by calculating, for each measurement frequency f, the resistance (a component of the impedance) of the chamber when target cells are present in the chamber (R 细胞 (f) Relative to the background resistance of the chamber when there are no cells but only cell culture medium in the chamber (R 背景 Relative change (f) = (R 细胞 (f)-R 背景 (f)) / R 背景 (f)), then, find the maximum relative change in resistance for all measured frequencies (cell index = maximum {relative change (f)} for all measured frequencies. The maximum relative change in resistance was used as the cell index. To quantitatively determine lysis at a specific time point, the cell index data was exported from the RT-CES software to Microsoft Excel, and the percentage of cell lysis at a specific E / T ratio at a given time was determined by comparing the cell index of the chamber with a specific E / T ratio with the cell index of the control chamber without NK cells added and calculating using the following equation: Cell lysis percentage = (1-CI 给定E / T比 / CI 没有NK细胞 )x100. Fig.29C , 31A Normalized cell index values were used in the calculation of the percentage of cell lysis of 31B, 31C, and 31D.
[0304] Cell lysis was determined using the MTT assay and crystal violet staining. Target cells grown on E-plates were incubated with effector cells at different ratios and incubated overnight. Cell lysis was dynamically monitored using the RT-CES system. At the end of the experiment, the chamber was washed with PBS to remove unbound cells, and the MTT reagent was used according to the manufacturer's protocol (Sigma), or the cells were fixed with 4% paraformaldehyde and then stained with a 0.1% crystal violet solution dissolved in H2O for 20 minutes to quantify the live cells attached to the bottom of the E-plate. The cells were washed five times to remove nonspecific stains, and the stained cells were dissolved overnight in the presence of 0.5% TX-100. The dissolved stain was measured using a microplate reader at a wavelength of 590nm.
[0305] Dynamic monitoring of NK-mediated cytolysis using the RT-CES system. To evaluate the effector cell-mediated cytotoxic activity against target cells, we used the NK-92 cell line. NK-92 is a human IL-2-dependent cell line derived from patients with non-Hodgkin's lymphoma that can be easily maintained and proliferated in culture and has very strong cytotoxic activity against different target cell lines (Gong et al., 1994). The NK-92 cell line and some of its derivatives are currently undergoing phase I clinical trials for the treatment of various cancers (Tam et al., 2003). To evaluate NK-92-mediated cytotoxicity, A549 lung cancer cells were seeded in ACEA E-plates at a density of 10,000 cells / chamber, and cell growth and proliferation were dynamically monitored using the RT-CES system. Twenty-four hours after seeding, NK cells were added at the indicated effector-target (E / T) ratio (Figure 29), and the degree of A549 cell viability was dynamically monitored. As Fig.29A As shown, the addition of NK-92 cells to A549 cells resulted in a density-dependent decrease in the A549 cell index over time, indicating that the NK-92 cells were inducing a cytotoxic effect on the A549 cells. The addition of NK-92 to the chamber without any A549 cells did not produce any noticeable change relative to background (data not shown). Moreover, A549 cells treated with medium alone continued to grow and proliferate ( Fig.29A To compare cell viability measured by the RT-CES system with standard assays, at the end of the experiment, the chamber of the E-plate was washed to remove NK cells and any dead cells, and the extent of target cell viability was determined by MTT assay. Fig.29B The comparison of the cell index readings and MTT at the end of the 50-hour experiment is shown. Overall, the correlation between the MTT readings and the cell impedance measurements of RT-CES is very good. In addition to MTT, crystal violet staining of target cells was performed in parallel, and the results verified the results of MTT (data not shown). The relative cytolytic activity of NK-92 cells against A549 target cells measured by both the RT-CES system and MTT at different E / T ratios is shown in Figure 2. Fig.29C As shown. Fig.29C , the RT-CES system is more sensitive than MTT in detecting cell lysis, especially at lower E / T ratios.
[0306] In addition to NK-92 cells, the cytotoxic activity of mouse NK cell lines (mNK) was also evaluated using the RT-CES system ( Fig.30 NIH 3T3 mouse fibroblast cell line was seeded in E-plates and grown overnight. Twenty-four hours after seeding, NK cells were added to the chamber at different E / T ratios, and the viability of NIH 3T3 cells was continuously monitored ( Fig.30As a control, YAC cells alone or culture medium alone were added to NIH 3T3 cells grown in an E-plate chamber. mNK cells induced a gradual decrease in the cell index, while the addition of YAC cells or culture medium alone had little effect on the cell index recording of NIH3T3 cells ( Fig.30 ). In order to confirm that the gradual decrease in cell index is related to cell lysis, the cells at the bottom of the E-plate were washed, fixed, and stained with Giemsa dye, and photographed using a CCD camera attached to a microscope (data not shown). The addition of YAC cells to the NIH 3T3 cells grown on the bottom of the E-plate had no detectable effect on the target cells, while the addition of mNK cells resulted in a large gap and area without target cells on the sensor at the bottom of the chamber, indicating that cell lysis had occurred. In short, the RT-CES system provides the possibility of monitoring the cytotoxic activity of effector cells mediated to adherent target cells in a non-invasive, label-free and dynamic manner.
[0307] The NK-mediated cytolysis of different target cells was dynamically monitored using the RT-CES system. The cytolytic activity of mNK and NK 92 was tested using 9 cell lines, including 8 different human cancer cell lines and the NIH 3T3 cell line. Tables 4 and 5 summarize the sensitivity of different target cell lines to mNK or NK 92-mediated cytolysis. NK 92 showed a wide range of cytolytic activity on cancer cell lines. NK 92-mediated cytolysis occurred rapidly and reached maximum killing activity before 8 hours after the addition of NK 92 cells. Among these 7 cancer target cell lines, 4 target cell lines achieved more than 90% cytolysis, including H460, HepG2, MCF7 and MDA-MB231. In contrast, mNK cell-mediated cytolysis (Table 4) appears to be more selective than NK 92 (Table 5). Among these 9 target cell lines, after incubation with mNK cells for 12 hours, 4 target cell lines, including NIH 3T3, A549, HeLa and MDA-MB231, showed more than 30% cell lysis, while no cell lysis (0%) or weak cell lysis (10%) was found in 5 target cell lines, including OVCR4, HT1080, HepG2, H460 and MCF7. In addition, the cell lysis mediated by mNK was much slower than that of NK 92, reaching the maximum value 12 hours after adding mNK cells.
[0308] Inhibition of NK-mediated cytolysis of target cells by agents that block the signaling pathways that lead to cytotoxicity. Interaction of target cells with NK receptors on the cell membrane leads to activation of signal transduction machinery, which results in cytolysis of target cells (Vivier et al., 2004). One of the key signaling cascades that regulates the fusion of perforin with granzyme-containing secretory granules at the NK / target cell synaptic junction is the phosphatidyl-inositol-3-kinase (PI3K), Rac, and mitogen-activated protein kinase 1 (Erk) pathway (Djeu et al., 2002; Vivier et al., 2004). To determine the specificity of the signaling pathway in regulating NK-mediated cytotoxicity, we sought to utilize specific inhibitors of the PI3K and Erk pathways. NK-92 cells were incubated with both the PI3K inhibitor wortmannin and the Erk pathway inhibitor PD98059, or with DMSO as a control, and then added to A549 target cells. As shown in Figure 31, as monitored by the RT-CES system, both wortmannin and PD98059 inhibited NK-92-mediated cell lysis of A549 cells in a dose-dependent manner. As an additional control, A549 target cells were also incubated with separate wortmannin and PD 98059, and the results had minimal effect on the baseline. We calculated the percentage inhibition of cell lysis by the two inhibitors at different time points after adding NK. Although Erk pathway inhibitors all resulted in consistent inhibition of cell lysis at all indicated time points ( Fig.31B ), but the inhibition of cell lysis mediated by PI3K inhibitors clearly depended on the time point at which the analysis was performed ( Fig.31D ). In short, the experiments shown here clearly demonstrate that the RT-CES system can be used to monitor NK-mediated cytotoxic activity against a variety of different cell lines. In addition, it is known that the cytotoxic reaction mediated by NK is interfered with by using an inhibitor of the signal transduction cascade regulating particle fusion, which significantly weakens the cytotoxic reaction. The data also show that the degree of inhibition depends mainly on the length of time that NK is incubated with target cells, and these data also provide a good theoretical basis for dynamically monitoring the cytotoxicity mediated by effector cells.
[0309] Discussion. NK cells play a central role in the innate immune response and serve as an intermediary in bridging the gap between innate and adaptive immunity (Lanier, 2005). NK cells have specialized organelles or granules that house cytolytic enzymes and proteins that exert their cytolytic activity when they encounter pathogen-infected cells or tumors (Smyth et al., 2002; Smyth et al., 2005). Recently, a number of receptors have been identified on the surface of NK cells that modulate NK-mediated cytotoxicity in a positive or negative manner depending on the identity of the target cell (Lanier, 2005).
[0310] In this report, we describe a label-free, real-time assay for monitoring NK-mediated cytotoxicity against different adherent target cells. This assay is based on monitoring the viability of target cells grown on an array of electronic cell sensors fabricated in the bottom chamber of a microtiter plate (E-plate). The interaction of the cells with the sensor produces an impedance response that indicates the general health of the cells. We have demonstrated using human and mouse NK cells that NK-mediated cytotoxic activity can be monitored using the RT-CES system, which consists of a monitoring system and E-PLATES, which includes microelectrodes for detecting target cells (Abassi et al., 2004; Solly et al., 2004; Xing et al., 2005). The NK-mediated cytotoxicity monitored on the RT-CES system was correlated with standard assays such as MTT and crystal violet staining of target cells to assess effector cell-mediated cytotoxicity (Figure 29). Both assays have been used to monitor effector cell-mediated cytolysis of target cells (Wahlberg et al., 2001; Peng et al., 2004). The release of granules containing lytic proteins and proteases is regulated by receptor-mediated signal transduction cascades. Specifically, the PI3K and ERK pathways have been shown to play a major role in granule exocytosis and cytotoxicity in addition to cytokine secretion (Djeu et al., 2002; Vivier et al., 2004). Using the RT-CES system and confirming earlier data, we were able to show that interference with the PI3K and Erk pathways by small molecule inhibitors blocks NK-mediated cytolysis of target cells (Figure 31). The extent of inhibition of cytolysis by different pathway blockers depends on the duration of incubation of NK cells with target cells ( Fig.31B and Fig.31D If a standard single-point assay such as the chromium release assay (CRA) is used, the time-dependent effect of the inhibitor on cell lysis will be easily missed. Example 8 BiTe-mediated cell killing of target cells
[0311] Immunotherapy is emerging as one of the most promising approaches in cancer treatment, enabling specific cancer cell killing mediated by cytotoxic T cells by recognizing specific markers expressed on the surface of cancer cells. Antibody-dependent cellular cytotoxicity (ADCC) is one of the first immunotherapeutic approaches to achieve clinical trials and involves the activity of different types of immune effector cells. In the chimeric antigen T-cell receptor (CAR-T) approach, the patient's T lymphocytes are engineered to express chimeric receptors that bind to tumor cell antigens and activate the cytotoxic activity of T cells. In contrast, bispecific T-cell engager (BiTE) antibodies are engineered bivalent proteins that promote the interaction between tumor cells and T lymphocytes by simultaneously binding to tumor cell markers and the T-cell-specific receptor CD3. Through this dual interaction, BiTE antibodies induce the formation of a cytolytic synapse, which leads to specific lysis of target tumor cells through a cascade of cytotoxic events, including the release of perforins and granzymes, which compromise the integrity of the cell membrane. Subsequently, the activation of caspases induces DNA fragmentation, morphological changes, and ultimately apoptosis of target cells.
[0312] To determine whether the use of BiTE antibodies could redirect immune cells to recognize and kill cancer cells, we used a specific EpCAM / CD3 BiTE on PC3 prostate cancer cells. Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that mediates Ca-independent adhesion kinases in epithelial cells. 2+ Cell-cell adhesion and is involved in cell signaling, migration, proliferation and differentiation. It is also overexpressed in many cancers, and these overexpressions contribute to proliferation and anti-apoptotic signals. Target PC3 cells were seeded on E-Plate 96 at a density of 10,000 cells / chamber and allowed to grow for 24 hours. Freshly isolated PBMCs were added to quadruplicate samples with EpCAM BiTE antibodies at an effector: target ratio of 20. CI was normalized to the last recorded data point before the addition of PBMCs. The addition of PBMCs alone failed to affect the growth of cancer cells, and the increase in the number of cancer cells was reflected in the increase in the normalized CI parameter for five consecutive days. The CI increase ended when the cells reached confluence ( Fig.32A , trace X). In contrast, in the presence of EpCAM BiTE, CI began to decrease towards 0 (initial background value measured before PC3 addition). The kinetics of CI decrease were proportional to the amount of BiTE, with the highest concentration inducing a decrease in CI only 12 hours after PBMC addition ( Fig.32A: diamond trace). The lowest concentration tested was still able to induce cell killing, but the initial CI drop was only visible 28 hours after the addition of effector cells. Furthermore, such concentrations did not appear to induce complete cell killing, with the CI curve reaching a plateau of 1 ( Fig.32A : triangle trace). Taken together, these data demonstrate the ability of the xCELLigence platform to detect differences in cell killing kinetics associated with BiTE titrations.
[0313] We also evaluated the ability of the xCELLigence platform to detect differences in killing kinetics due to changes in the effector:target ratio. This is of particular interest because, although the contribution of immune cells to CI is negligible, there is still the possibility that changes in the linearity of CI due to PBMC numbers may affect the ability to compare samples with different ratios. In addition, cancer patients often require multiple cycles of chemotherapy and are immunocompromised. Therefore, it is of great interest to evaluate whether even small numbers of immune cells can be effectively activated in the presence of BiTEs. Fig.32B In the experiments described, we kept the EpCAM / CD3 BiTE at a constant concentration of 1 μg / ml, while varying the effector:target ratio. Each concentration of effector cells was effective in killing cancer cells, and even equimolar ratios of PBMC and PC3 were still able to induce effective killing of cancer cells, albeit with longer kinetics and incomplete killing ( Fig.32B , black squares). Such sensitivity is difficult to achieve using endpoint methods such as chromium-51 and flow cytometry. Samples without PBMCs ( Fig.32B , black circles) have a similar profile to the control without BiTEs, indicating that immune cells alone have little effect on CI measurements.
[0314] Different strategies developed for cancer immunotherapy rely on the specific targeting of cancer cells by the immune system through antigens expressed on their surface. However, due to the heterogeneity of almost all solid tumors, differences in the expression levels of target antigens may affect the efficiency of cell killing, with a huge impact on treatment outcome. We utilized three different cancer cell lines to test whether the kinetics of cell killing could be affected by the amount of surface EpCAM expression. We used a NovoCyte flow cytometer (ACEA Biosciences) to measure the surface levels of EpCAM in PC3 prostate, MCF 7 breast, and HeLa cervical human cancer cell lines ( Fig.33A). MCF7 expressed the highest level of antigen, while PC3 expressed only one-tenth of that, with only a very small subpopulation showing the same intensity as MCF7. Half of the HeLa population did not express EpCAM, while the remaining cells did express EpCAM, but at an intensity 1 / 100 of that of MCF7 and 1 / 10 of that of PC3. It can be seen that these three cell lines represent a continuous spectrum of EpCAM antigenic variation.
[0315] In a separate experiment, we treated these three different cell lines with the same amount of EpCAM BiTE antibody and PBMC:cancer cell ratio ( Fig.33B ). In MCF7, the addition of PBMCs induced an immediate increase in the cell index, which then decreased and reached a value of 0 in less than 90 hours, while in PC3, the same antibody required more than 115 hours to reach a stable level, which remained above 0. The initial CI increase was also delayed by 4 hours compared to MCF7. In HeLa, the same antibody still induced an initial CI increase, which then gradually decreased, but slower than the other two cancer cell lines.
[0316] To better identify kinetic differences associated with EpCAM expression and the amount of PBMC added, we used control chambers treated with antibody but without PBMC to establish a baseline against which each different amount of effector cell ratio was plotted as relative change. This baseline was normalized for each cell line using the corresponding control group, and the curves were combined in a single graph for each BiTE concentration ( Fig.33C ). This color-coded plot immediately highlights the differences in kinetics between the experimental conditions. In all cell lines, the negative slope of the curves decreased when the number of effector cells decreased ( Fig.33C : from dark to light). Even the time at which the decreasing curve intersects the horizontal axis increases in proportion to the lower PBMC number. This point marks a good approximation of the time when cell killing is affecting the majority of cancer cells. Comparing the different cell lines, the difference in kinetics is clearly seen, with MCF7 starting to decline in CI several days before PC3 and HeLa.
[0317] The dependence on antibody concentration and effector:target ratio is also reflected in the ET50 parameter ( Fig.33D ), where MCF7 showed shorter times at all cell ratios, while HeLa decreased to a value of 50% only at the highest effector cell ratio.
[0318] In summary, these experiments demonstrate the high sensitivity of impedance-based methods to measure cytotoxic activity in complex experimental designs. The ability to obtain the full dynamics of the response over a time scale provides the potential for better characterization of agent efficacy and also helps to better understand the dynamics of cell killing as it relates to cancer cell type and number of effector cells. Such detailed analysis would be impossible or laborious if endpoint assays such as 51Cr release or flow cytometry were used. In contrast, the xCELLigence platform allows for rapid and easy setup of high-throughput experiments with multiple doses and replicates, as it is simple to set up and does not require any labeling steps. In addition, the absence of any labeling also provides the potential for secondary analysis of the same cells. Example 9 B cell killing assay using cell-matrix impedance monitoring
[0319] Daudi B lymphoblasts were labeled with 5 mM Cell Trace Violet (Thermo Fisherscience) at 37°C for 20 minutes and seeded at a density of 80,000 cells / chamber onto chambers coated with 1 μg / ml goat anti-human IgM (25 ul) overnight at 4°C. The next day, Tall-104 T lymphoblasts ( Fig.34A ). The total volume between the chambers was kept constant. CI measurements were performed every 15 minutes during 54 hours.
[0320] Before adding Tall-104, CI plots were normalized at the last read ( Fig.34A ). The slope on the normalized curve was measured during the first 10 hours after the addition of Tall-104. The CI plot showed a good dose-response killing of B cells that was proportional to the effector cell ratio. All concentrations except two showed a time-dependent decrease in CI. 0.078:1 had an immediate cell growth inhibitory effect with a constant CI. 0.039:1 slowed the rise in CI compared to the no Tall-104 sample. The same progression can be seen in the slope plot. No Tall-104 and the lowest concentration had a positive slope, while all other concentrations had dose-dependent negative values ( Fig.34B ). The Daudi only and Tall-104 only plots show that Tall-104 had a negligible effect on the CI of the IgM coated plates. The Tall-104 plots are reported for the largest amount of Tall-104 (1.25:1) ( Fig.34C ).
[0321] In another example, Daudi cells were fixed at a density of 80,000 cells / chamber in an E-PLATE 96 pre-coated with an anti-CD40 antibody. Effector cells (NK-92) were added in varying amounts 19.9 hours after inoculation of the Daudi cells. The impedance was then monitored for an additional 70 hours. The raw impedance data was collected, averaged, normalized, and then the negative control trace, i.e., the B cell trace when no effector cells were added, was subtracted. The results show that B cells can indeed be bound to the bottom of the chamber by antibodies (in this case, antibodies against CD40), and effector cell-mediated cytotoxicity can then be monitored.
[0322] In summary, the present invention includes but is not limited to the following: 1. A method for evaluating cytolysis of cancer cells, the method comprising: a) providing a cell-matrix impedance monitoring box comprising a plurality of chambers, each chamber having an electrode array configured to measure cell-matrix impedance, wherein different chambers are pre-loaded with different target cells, specifically cancer cells of different lineages, origins or stages; b) adding effector cells to the plurality of chambers to interact with target cells, wherein the effector cells are immune cells; c) monitoring cell-matrix impedance of the plurality of chambers before and after adding effector cells, and optionally deriving impedance-based parameters from the impedance; and d) determining the effectiveness of effector cells in killing different target cells by comparing said impedance or impedance-based parameters over time. 2. The method according to item 1, wherein the different target cells are pre-loaded by a facility that maintains cancer cells from different tissue origins, and the method further comprises receiving a box pre-loaded with the different target cells for delivery. 3. A method according to claim 2, wherein the different tissue origins include at least one tissue origin selected from the group consisting of breast tissue, lung tissue, colon tissue, mesenchymal cells or fibroblasts (e.g., fibrosarcoma), prostate tissue, kidney tissue, epidermal tissue, liver tissue, and ovarian tissue. 4. A method according to claim 1, wherein the box fluid is connected to a pump, which pumps cell culture or fluid into the multiple chambers. 5. A method according to claim 1, wherein the box fluid is connected to an external cell culture device, which is configured to culture the effector cells before adding to the multiple chambers, and the cell culture device is optionally embodied as a bioreactor. 6. The method according to item 5, wherein the cell culture device is a bioreactor, and the bioreactor is a wave rocking bioreactor. 7. A method according to item 1, wherein the box includes a channel system configured to input fluid into the chamber and output the chamber, and the box optionally has a sealed top. 8. A method according to item 7, wherein the channel system is configured with ports for delivering gas into and out of the box. 9. A method according to claim 7, wherein the channel system is configured to receive effector cells from an external cell culture device that is fluidically connected to the box. 10. The method according to item 1, wherein the effector cells are selected from the group consisting of natural killer cells (NK cells), macrophages, neutrophils, eosinophils, T cells and B cells. 11. A method according to claim 1, wherein the effector cells are chimeric antigen receptor T cells (CAR-T cells). 12. A method according to claim 11, wherein the chimeric antigen receptor (CAR) displays a single-chain fragment variable (scFv) region, and optionally displays multiple scFVs. 13. The method according to claim 1, wherein the effector cells are engineered to increase the expression of an exogenous compound (optionally interleukin 2) to promote the growth, proliferation or persistence of the effector cells. 14. The method of claim 1, wherein the impedance-based parameter is the Cell Index, or a normalized Cell Index normalized to a time point prior to addition of effector cells. 15. A method for evaluating cytolytic activity against cancer cells, the method comprising: a) providing a cell-matrix impedance monitoring box comprising a plurality of chambers, each chamber having an electrode array configured to monitor cell-matrix impedance, wherein different chambers are pre-loaded with different target cells, specifically cancer cells of different lineages, origins or stages; b) adding effector cells to the plurality of chambers, wherein the effector cells are immune cells; c) adding a bispecific linker to at least some of the chambers, wherein the bispecific linker is a molecule suspected of bridging the effector cells to at least some of the target cells; d) monitoring the cell-matrix impedance of the plurality of chambers over time, including before and after the step of adding the bispecific linker, and optionally deriving an impedance-based parameter from the impedance; and e) determining the effectiveness of killing of different target cells by effector cells in response to the bispecific adaptor by comparing said impedance or impedance-based parameters over time. 16. The method according to item 15, wherein the different target cells are pre-loaded by a facility that maintains cancer cells from different tissue origins, the method further comprising receiving a box pre-loaded with the different target cells for delivery. 17. A method according to claim 16, wherein the different tissue origins include at least one tissue origin selected from the group consisting of breast tissue, lung tissue, colon tissue, mesenchymal cells or fibroblasts (e.g., fibrosarcoma), prostate tissue, kidney tissue, epidermal tissue, liver tissue, and ovarian tissue. 18. A method according to claim 15, wherein the box is fluidly connected to a pump, which pumps the cell culture, the bispecific linker and / or fluid into the multiple chambers. 19. A method according to claim 15, wherein the box is fluidly connected to an external cell culture device, which is configured to culture the effector cells before adding to the plurality of chambers, and the cell culture device is optionally embodied as a bioreactor. 20. The method of claim 19, wherein the cell culture device is a bioreactor, and the bioreactor is a wave-swing bioreactor. 21. A method according to claim 15, wherein the box includes a channel system configured to transport cell culture or fluid to the multiple chambers, and the box optionally has a sealed top. 22. A method according to item 21, wherein the channel system is configured with ports for delivering gas into and out of the box. 23. A method according to claim 21, wherein the channel system is configured to receive effector cells from an external cell culture device that is fluidically connected to the box. 24. A method according to claim 21, wherein the channel system is configured to receive a bispecific linker from a reagent reservoir fluidly connected to the box. 25. The method according to item 15, wherein the effector cells are selected from the group consisting of natural killer cells (NK cells), macrophages, neutrophils, eosinophils, T cells and B cells. 26. The method according to item 25, wherein the T cells are selected from one or more of the following groups: helper T cells (Th cells), cytotoxic T cells and memory T cells. 27. A method according to claim 15, wherein the bispecific linker comprises two polypeptides linked together, each of which binds to effector cells or at least some target cells, thereby bridging the effector cells and at least some target cells. 28. A method according to claim 15, wherein the bispecific linker binds to a T cell surface module, optionally binding to cluster of differentiation 3 (CD3). 29. A method according to claim 15, wherein the impedance-based parameter is the cell index, or a normalized cell index normalized to a time point before addition of the bispecific linker. 30. The method of clause 15, wherein a decrease in impedance or an impedance-based parameter indicates an increase in effectiveness. 31. A method of assessing cytolysis of cancer cells, the method comprising: a) providing a cell-matrix impedance monitoring cassette fluidically coupled to a bioreactor and a pump, the cassette comprising a chamber having an electrode array configured to measure cell-matrix impedance; b) adding target cells to the chamber and culturing the cells in the bioreactor; c) pumping cells from the cell culture into the chamber; d) monitoring the cell-matrix impedance of the chamber before and after adding cells from the cell culture, and optionally deriving an impedance-based parameter from the impedance; and e) determining changes in the cell-matrix impedance or impedance-based parameter in response to pumping cells into the chamber. 32. A method according to claim 31, wherein the target cells are cancer cells and the cells in the cell culture are effector cells. 33. A method according to claim 31, wherein the bioreactor is a wave-swaying bioreactor. 34. A method according to item 31, wherein the box includes a channel system configured to transfer fluid into and out of the chamber, and the box optionally has a sealed top. 35. A method according to item 31, wherein the channel system is configured with ports for delivering gas into and out of the box. 36. A method according to claim 31, wherein the cells in the cell culture are selected from the group consisting of natural killer cells (NK cells), macrophages, neutrophils, eosinophils, T cells and B cells. 37. A method according to claim 31, wherein the cells in the cell culture are chimeric antigen receptor T cells (CAR-T cells). 38. A method according to claim 37, wherein the chimeric antigen receptor (CAR) displays a single-chain fragment variable (scFv) region, optionally displaying multiple scFVs. 39. A method according to claim 31, wherein the cells in the cell culture are engineered to increase the expression of an exogenous compound (optionally interleukin 2) to promote the growth, proliferation or persistence of the cells in the cell culture. 40. A method according to item 31, wherein the impedance-based parameter is the Cell Index, or a normalized Cell Index normalized to a time point prior to addition of effector cells. 41. The method of claim 31, further comprising adding a bispecific linker to the chamber. 42. A cell-matrix impedance monitoring system, comprising: a) a cell-matrix impedance monitoring cassette comprising a plurality of chambers, each chamber having an electrode array configured to measure cell-matrix impedance; b) a bioreactor configured for culturing cells, the bioreactor being fluidically coupled to the cartridge; c) a pump configured to pump cultured cells from the bioreactor into the plurality of chambers of the cassette; and d) an impedance analyzer, electrically connected to the electrode array, for measuring the cell-matrix impedance in the plurality of chambers.
Claims
1. A method for evaluating cytolysis of cancer cells, the method comprising: a) providing a cell-matrix impedance monitoring box comprising a plurality of chambers, each chamber having an electrode array configured to measure cell-matrix impedance, wherein different chambers are pre-loaded with different target cells, specifically cancer cells of different lineages, origins or stages; b) adding effector cells to the plurality of chambers to interact with target cells, wherein the effector cells are immune cells; c) monitoring cell-matrix impedance of the plurality of chambers before and after adding effector cells, and optionally deriving impedance-based parameters from the impedance; and d) determining the effectiveness of effector cells in killing different target cells by comparing said impedance or impedance-based parameters over time.
2. The method of claim 1, wherein the different target cells are preloaded by a facility that maintains cancer cells from different tissue origins, the method further comprising receiving a delivery of a cartridge preloaded with the different target cells.
3. The method of claim 2, wherein the different tissue origins include at least one tissue origin selected from the group consisting of breast tissue, lung tissue, colon tissue, mesenchymal cells or fibroblasts (e.g., fibrosarcoma), prostate tissue, kidney tissue, epidermal tissue, liver tissue, and ovarian tissue.
4. The method of claim 1, wherein the cartridge is fluidly connected to a pump that pumps cell culture or fluid into the plurality of chambers.
5. The method of claim 1, wherein the cartridge is fluidly connected to an external cell culture device configured to culture the effector cells prior to addition to the plurality of chambers, the cell culture device optionally being embodied as a bioreactor.
6. The method of claim 5, wherein the cell culture device is a bioreactor, and the bioreactor is a wave rocking bioreactor.
7. The method of claim 1, wherein the cartridge comprises a channel system configured to transfer fluid into and out of the chamber, the cartridge optionally having a sealed top.
8. The method of claim 7, wherein the channel system is configured with ports for delivering gas into and out of the cartridge.
9. The method of claim 7, wherein the channel system is configured to receive effector cells from an external cell culture device fluidically connected to the cartridge.
10. The method of claim 1, wherein the effector cells are selected from the group consisting of natural killer cells (NK cells), macrophages, neutrophils, eosinophils, T cells, and B cells.
